## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-02-24_Virtual Town Hall 44_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/146427/download?attachment
link youtube: https://youtu.be/owdGSBGw7hw
link slides: 
topic: COVID-19


## content

### qa


#### 2. Usability vs. User Comprehension Studies in IVD Testing

QA Block 2-1
CLARIFIED QUESTION: What is the difference between usability studies and user comprehension studies in the validation process for COVID-19 diagnostic tests?
CLARIFIED ANSWER: Usability studies evaluate whether users can properly use the device without serious errors, involving observational testing, sample assessments, and questionnaires. User comprehension studies assess users' understanding of critical labeling elements, particularly important for tests without healthcare provider involvement.
VERBATIM QUESTION: What is the difference between usability studies and user comprehension studies in the validation process for COVID-19 diagnostic tests?
VERBATIM ANSWER: Usability studies assess whether the intended user of the device can use the device properly without serious use errors or problems. And this testing typically would include an observational specimen of the users performing the testing, an assessment of the sample collected or the testing performed by the intended user and an interviewer questionnaire to assess the users' perspectives on the usability of the device. Our current template for molecular and antigen diagnostic tests for tests outside of healthcare settings the - and we refer to it as the non-lab or the home use test - or sorry template, does include a recommendation to assess the users' perspective on the usability of the device using a questionnaire consistent with the recommendations and our 2016 human factors guidance. I will note that the question last week referred to that 2016 human factors guidance. And I do want to point out that some of the details in that guidance while they are, the general concepts are applicable to IVDs, the - there are specific details that are necessary to consider for IVDs since the guidance document is written for evaluating user interfaces which is different from evaluating an IVD where that involves collecting a sample and performing a test as opposed to simply interfacing with a user interface. So that's - those are usability studies. And then separate from usability studies there are user comprehension studies. User comprehension studies are intended to objectively assess the intended users' understanding or comprehension of critical elements and concepts in the labeling. These studies are particularly important for tests that are intended for use by the users that do not include the involvement of a healthcare provider. The current template for non-lab tests does not discuss user comprehension studies but we do think that this is very important to assess especially for tests NWX-FDA OC where there's not healthcare provider involvement to consider user comprehension and assess the comprehension of labeling for devices where the results are returned to the lay user.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Usability studies, User comprehension studies, Validation process
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Why does the FDA recommend using questionnaires consistent with the 2016 human factors guidance for usability studies of diagnostic devices?
CLARIFIED ANSWER: The FDA recommends using questionnaires consistent with the 2016 human factors guidance in usability studies to assess user perspectives on device usability. The guidance is generally applicable to IVDs but requires specific considerations because IVD usability involves sample collection and testing rather than user interface interaction.
VERBATIM QUESTION: Why does the FDA recommend using questionnaires consistent with the 2016 human factors guidance for usability studies of diagnostic devices?
VERBATIM ANSWER: Our current template for molecular and antigen diagnostic tests for tests outside of healthcare settings the - and we refer to it as the non-lab or the home use test - or sorry template, does include a recommendation to assess the users' perspective on the usability of the device using a questionnaire consistent with the recommendations and our 2016 human factors guidance. I will note that the question last week referred to that 2016 human factors guidance. And I do want to point out that some of the details in that guidance while they are, the general concepts are applicable to IVDs, the - there are specific details that are necessary to consider for IVDs since the guidance document is written for evaluating user interfaces which is different from evaluating an IVD where that involves collecting a sample and performing a test as opposed to simply interfacing with a user interface.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: usability studies, human factors guidance, IVD device validation
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What are the specific considerations for usability studies of IVDs compared to other types of user interface evaluations?
CLARIFIED ANSWER: Usability studies for IVDs assess whether the intended user can properly complete tasks such as collecting a sample and performing the test, rather than just interacting with a user interface. Additional considerations include an observational study of user actions, sample assessment, and a questionnaire, based on 2016 human factors guidance. Specific considerations for IVDs arise because they involve sample collection and testing.
VERBATIM QUESTION: What are the specific considerations for usability studies of IVDs compared to other types of user interface evaluations?
VERBATIM ANSWER: Usability studies assess whether the intended user of the device can use the device properly without serious use errors or problems. And this testing typically would include an observational specimen of the users performing the testing, an assessment of the sample collected or the testing performed by the intended user and an interviewer questionnaire to assess the users' perspectives on the usability of the device. Our current template for molecular and antigen diagnostic tests for tests outside of healthcare settings the - and we refer to it as the non-lab or the home use test - or sorry template, does include a recommendation to assess the users' perspective on the usability of the device using a questionnaire consistent with the recommendations and our 2016 human factors guidance. I will note that the question last week referred to that 2016 human factors guidance. And I do want to point out that some of the details in that guidance while they are, the general concepts are applicable to IVDs, the - there are specific details that are necessary to consider for IVDs since the guidance document is written for evaluating user interfaces which is different from evaluating an IVD where that involves collecting a sample and performing a test as opposed to simply interfacing with a user interface.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: IVD usability studies, Human factors guidance, IVD-specific considerations
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Why doesn't the current template for non-lab tests include user comprehension studies, and when might these be added?
CLARIFIED ANSWER: The current template for non-lab tests does not address user comprehension studies, but FDA recognizes their importance, particularly when no healthcare provider is involved. For serology tests, FDA is working on a template due to risks of user misinterpretation and misuse.
VERBATIM QUESTION: Why doesn't the current template for non-lab tests include user comprehension studies, and when might these be added?
VERBATIM ANSWER: The current template for non-lab tests does not discuss user comprehension studies but we do think that this is very important to assess especially for tests where there's not healthcare provider involvement to consider user comprehension and assess the comprehension of labeling for devices where the results are returned to the lay user. And I want to note particularly for serology tests -- and we are currently working on a template to provide recommendations for validation for serology tests performed outside of healthcare settings, there are significant risks associated with lay user misinterpretation and misuse of serology tests since they should not be used to diagnose acute infection and its unknown whether antibodies confirm immunity or protection from infection and if so how long that may last. The clinical significance of serology test results especially in individuals that have received vaccine is unknown.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: user comprehension studies, template updates, lay user risks
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: What does the FDA recommend for addressing the risks of lay user misinterpretation of serology test results?
CLARIFIED ANSWER: The FDA highlights the need to assess user understanding of serology testing, including its limitations, due to risks of lay user misinterpretation and misuse. Serology tests should not diagnose acute infection, and the clinical significance of antibody presence remains uncertain.
VERBATIM QUESTION: What does the FDA recommend for addressing the risks of lay user misinterpretation of serology test results?
VERBATIM ANSWER: And I want to note particularly for serology tests -- and we are currently working on a template to provide recommendations for validation for serology tests performed outside of healthcare settings, there are significant risks associated with lay user misinterpretation and misuse of serology tests since they should not be used to diagnose acute infection and its unknown whether antibodies confirm immunity or protection from infection and if so how long that may last. The clinical significance of serology test results especially in individuals that have received vaccine is unknown. So given the current limitations of serology testing, lay users may misunderstand and potentially misuse serology test results. So it's particularly important to assess the users understanding of the test including its limitation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Lay user risks, Serology test limitations, FDA recommendations
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: What are the FDA's priorities for reviewing COVID-19 diagnostic tests, especially in different test categories (e.g., over-the-counter, prescription, point of care)?
CLARIFIED ANSWER: The FDA prioritizes reviewing COVID-19 tests such as home over-the-counter tests, home prescription tests, point-of-care tests, and high-throughput central lab tests, focusing on both molecular and antigen diagnostics.
VERBATIM QUESTION: What are the FDA's priorities for reviewing COVID-19 diagnostic tests, especially in different test categories (e.g., over-the-counter, prescription, point of care)?
VERBATIM ANSWER: I just want to reemphasize our current priorities for review at the FDA for tests. So obviously home over-the-counter tests including rapid antigen tests are a high priority as well as home prescription tests including rapid antigen tests. Also a point of care test including rapid antigen tests as well as extremely high throughput central lab tests pretty much of any sort. We're really looking for both molecular and antigen, the diagnostic test for the high throughput systems.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test review priorities, Test categories, FDA diagnostic focus
REVIEW FLAG: False


#### 3. Safety of Nasal Swabs for Children Under 14

QA Block 3-2
CLARIFIED QUESTION: Does the FDA have data suggesting that nasal swabs with no stopper are unsafe for children under 14 even for anterior nasal swabs?
CLARIFIED ANSWER: The FDA does not have data suggesting harm from anterior nasal swabs without a stopper, but developers are encouraged to consider safety features even for these swabs.
VERBATIM QUESTION: Does the FDA have data suggesting that nasal swabs with no stopper are unsafe for children under 14 even for anterior nasal swabs?
VERBATIM ANSWER: So we're interested in safety in the home environment and especially when untrained non-healthcare people are doing swabbing at home. So for an anterior nasal swab it's clearly shown and in the study shows there's no harm done, that's good. If you're going to go further in than an anterior nasal swab such as a mid- turbinate swab that's at the point that we would like some sort of safety NWX-FDA OC features. And certainly we encourage developers to even for anterior nasal swabs to think about safety in that situation.
SPEAKER QUESTION: Ariana Perez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: safety of nasal swabs for children, FDA recommendations, use of stoppers in swabs
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Is it acceptable for anterior nasal swabs to not have a stopper?
CLARIFIED ANSWER: FDA notes that while a stopper would be ideal, other mitigations like adapters can be used to ensure children's safety during swabbing.
VERBATIM QUESTION: Is it acceptable for anterior nasal swabs to not have a stopper?
VERBATIM ANSWER: A stopper would be ideal. There are potential other mediations on the different sort of swabs with, you know, some sort of adapter that some developers have used, but something yes to make sure that the children are safe when they're getting swabbed.
SPEAKER QUESTION: Ariana Perez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: anterior nasal swab design, use of stopper for safety
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Is the FDA requesting stoppers for mid-turbinate swabs?
CLARIFIED ANSWER: The FDA considers a stopper ideal for mid-turbinate swabs to ensure safety but notes alternative solutions like adapters may also be acceptable.
VERBATIM QUESTION: Is the FDA requesting stoppers for mid-turbinate swabs?
VERBATIM ANSWER: A stopper would be ideal. There are potential other mediations on the different sort of swabs with, you know, some sort of adapter that some developers have used, but something yes to make sure that the children are safe when they're getting swabbed.
SPEAKER QUESTION: Ariana Perez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mid-turbinate swab safety, use of stoppers, pediatric testing
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What specific safety measures, other than stoppers, does the FDA recommend for nasal swabs to ensure safety when used by non-healthcare individuals at home?
CLARIFIED ANSWER: The FDA recommends potential additional safety features, such as adapters on swabs, to ensure safety for children during swabbing.
VERBATIM QUESTION: What specific safety measures, other than stoppers, does the FDA recommend for nasal swabs to ensure safety when used by non-healthcare individuals at home?
VERBATIM ANSWER: There are potential other mediations on the different sort of swabs with, you know, some sort of adapter that some developers have used, but something yes to make sure that the children are safe when they're getting swabbed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: safety measures for nasal swabs, home use by non-healthcare individuals, children safety
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: Are adapters or other modifications, apart from stoppers, acceptable for ensuring the safety of children during home-based anterior or mid-turbinate swab testing?
CLARIFIED ANSWER: FDA considers stoppers ideal for ensuring child safety during swab testing, but developers may also use other options such as adapters to achieve this goal.
VERBATIM QUESTION: Are adapters or other modifications, apart from stoppers, acceptable for ensuring the safety of children during home-based anterior or mid-turbinate swab testing?
VERBATIM ANSWER: A stopper would be ideal. There are potential other mediations on the different sort of swabs with, you know, some sort of adapter that some developers have used, but something yes to make sure that the children are safe when they're getting swabbed.
SPEAKER QUESTION: Ariana Perez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: child safety during swab testing, use of stoppers or adapters, home-based testing
REVIEW FLAG: False


#### 4. Guidance on Serology Tests and Mutation Impact Evaluation

QA Block 4-2
CLARIFIED QUESTION: Is there any guidance on how to evaluate the performance of a serology test?
CLARIFIED ANSWER: FDA recommends analyzing the serology test's viral epitope for mutations using public databases and assessing impacts of changes. Developers should evaluate whether prevalent mutations affect performance and potentially use immune serum from patients carrying such mutations, though this is risk-based.
VERBATIM QUESTION: Is there any guidance on how to evaluate the performance of a serology test?
VERBATIM ANSWER: So for serology tests there's, you know, current thinking is there's, you know, some things that we can do. For example every serology developer would know the epitope that's of the virus that's being used. They know the sequence of amino acids. So you can check the known public databases for any prevalence mutations that impact the new assay sequence of your epitope in your assay. NWX-FDA OC Only if it does impact directly your epitope or if you have the means of assessing whether it's amino acid change outside the epitope could impact things. But I think, you know, right now the best way to go about this is to look at that epitope antigen that you're using in your assay and make sure there aren't any prevalent. And we usually use the 5% rule but check out the guidance 5% or below or 5% in total or below or it doesn't push the performance for the assay down below what we would usually expect to see for authorization. And obviously if you do have an epitope that has a prevalent mutation that leads to an amino acid change, you'll want to assess what the potential impact on that amino acid change is. Is it something - is it, you know, something shouldn't actually change too much, you know, it may be a very similar, you know, amino acid. But in all likelihood if it's changing amino acid, it may be due to immune function that may allow it to somewhat evade the patient's immune system. And so then how do you know beyond that for serology tests if it impacts? And that would probably involve trying to find immune serum or plasma by from a patient who carries that mutation or variant in order to assess that. But again it's all risk-based, so if that mutation or variant is less prevalent right now we may just authorize the test with labeling that says, you know, there's a potential, you know, problem with this mutation or with this assay.
SPEAKER QUESTION: Dee Dee Datra
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test evaluation, mutation impact, test performance guidelines
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Can FDA recommend a source to obtain specimens positive for the most prevalent mutations right now?
CLARIFIED ANSWER: The FDA suggests immune plasma or serum from a patient exposed to the virus genotype affecting the assay, but currently does not have a recommendation or solution for obtaining such specimens.
VERBATIM QUESTION: Can FDA recommend a source to obtain specimens positive for the most prevalent mutations right now?
VERBATIM ANSWER: Yes it would be in the case of serology tests it would be immune plasm or serum from a patient known to have been exposed by the virus that could - genotype that could impact your assay. So that's obviously going to be a challenging sample for anybody to accumulate. So we're certainly in the process of looking into that. but I have no solution. I have no recommendation at this point unfortunately.
SPEAKER QUESTION: Dee Dee Datra
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Specimen sourcing, Serology tests, Mutation challenges
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: What does the FDA mean by the 5% rule when evaluating mutations?
CLARIFIED ANSWER: The FDA uses the 5% rule to evaluate mutations, indicating that mutations with a prevalence of 5% or below should not reduce assay performance below expected authorization standards.
VERBATIM QUESTION: What does the FDA mean by the 5% rule when evaluating mutations?
VERBATIM ANSWER: And we usually use the 5% rule but check out the guidance 5% or below or 5% in total or below or it doesn't push the performance for the assay down below what we would usually expect to see for authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 5% rule, mutation evaluation, assay performance
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: How should a serology test developer assess the impact of non-epitope amino acid changes on assay performance?
CLARIFIED ANSWER: FDA recommends examining public databases for prevalent mutations affecting the epitope's amino acid sequence, assessing their impact on assay performance using guidance thresholds like a 5% prevalence rule. Developers might also use serological samples from patients with relevant variants to evaluate performance.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So for serology tests there's, you know, current thinking is there's, you know, some things that we can do. For example every serology developer would know the epitope that's of the virus that's being used. They know the sequence of amino acids. So you can check the known public databases for any prevalence mutations that impact the new assay sequence of your epitope in your assay. NWX-FDA OC Only if it does impact directly your epitope or if you have the means of assessing whether it's amino acid change outside the epitope could impact things. But I think, you know, right now the best way to go about this is to look at that epitope antigen that you're using in your assay and make sure there aren't any prevalent. And we usually use the 5% rule but check out the guidance 5% or below or 5% in total or below or it doesn't push the performance for the assay down below what we would usually expect to see for authorization. And obviously if you do have an epitope that has a prevalent mutation that leads to an amino acid change, you'll want to assess what the potential impact on that amino acid change is. Is it something - is it, you know, something shouldn't actually change too much, you know, it may be a very similar, you know, amino acid. But in all likelihood if it's changing amino acid, it may be due to immune function that may allow it to somewhat evade the patient's immune system. And so then how do you know beyond that for serology tests if it impacts? And that would probably involve trying to find immune serum or plasma by from a patient who carries that mutation or variant in order to assess that. But again it's all risk-based, so if that mutation or variant is less prevalent right now we may just authorize the test with labeling that says, you know, there's a potential, you know, problem with this mutation or with this assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test mutation impact, amino acid changes, assay performance evaluation
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What are the risks involved in testing against less prevalent mutations or variants?
CLARIFIED ANSWER: The FDA uses a risk-based approach for less prevalent mutations or variants, potentially authorizing tests with labeling warning of a potential issue with the mutation or assay.
VERBATIM QUESTION: What are the risks involved in testing against less prevalent mutations or variants?
VERBATIM ANSWER: But again it's all risk-based, so if that mutation or variant is less prevalent right now we may just authorize the test with labeling that says, you know, there's a potential, you know, problem with this mutation or with this assay. But hopefully that's helpful enough and we hope, you know, that that immune serum will be available to developers.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Testing risks with less prevalent mutations, Labeling concerns for mutations
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: What is the process for obtaining immune serum or plasma to assess the impact of specific mutations?
CLARIFIED ANSWER: For serology tests, immune serum or plasma from a patient exposed to a relevant virus genotype is needed, which can be challenging to obtain. The FDA is exploring this but has no current solution or recommendations.
VERBATIM QUESTION: What is the process for obtaining immune serum or plasma to assess the impact of specific mutations?
VERBATIM ANSWER: Yes it would be in the case of serology tests it would be immune plasm or serum from a patient known to have been exposed by the virus that could - genotype that could impact your assay. So that's obviously going to be a challenging sample for anybody to accumulate. So we're certainly in the process of looking into that. but I have no solution. I have no recommendation at this point unfortunately.
SPEAKER QUESTION: Dee Dee Datra
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Obtaining immune serum, Assessing mutations, Serology testing
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: What labeling requirements might apply to tests if significant mutations are detected?
CLARIFIED ANSWER: FDA may authorize a test with labeling indicating a potential issue if a detected mutation or variant is less prevalent and impacts the test's performance.
VERBATIM QUESTION: What labeling requirements might apply to tests if significant mutations are detected?
VERBATIM ANSWER: But again it's all risk-based, so if that mutation or variant is less prevalent right now we may just authorize the test with labeling that says, you know, there's a potential, you know, problem with this mutation or with this assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: labeling requirements, mutation impact, test authorization
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: Is there specific guidance on evaluating assay epitopes for prevalent mutations and their effects?
CLARIFIED ANSWER: FDA recommends that developers evaluate assay epitopes using public databases to check for prevalent mutations affecting the epitope sequence. Developers should assess whether these mutations impact assay performance based on the 5% guidance or lead to amino acid changes that may affect immune response.
VERBATIM QUESTION: Is there specific guidance on evaluating assay epitopes for prevalent mutations and their effects?
VERBATIM ANSWER: For serology tests there's, you know, current thinking is there's, you know, some things that we can do. For example every serology developer would know the epitope that's of the virus that's being used. They know the sequence of amino acids. So you can check the known public databases for any prevalence mutations that impact the new assay sequence of your epitope in your assay. Only if it does impact directly your epitope or if you have the means of assessing whether it's amino acid change outside the epitope could impact things. But I think, you know, right now the best way to go about this is to look at that epitope antigen that you're using in your assay and make sure there aren't any prevalent. And we usually use the 5% rule but check out the guidance 5% or below or 5% in total or below or it doesn't push the performance for the assay down below what we would usually expect to see for authorization. And obviously if you do have an epitope that has a prevalent mutation that leads to an amino acid change, you'll want to assess what the potential impact on that amino acid change is.
SPEAKER QUESTION: Dee Dee Datra
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: assay epitope evaluation, prevalent mutations, serology test guidance
REVIEW FLAG: False


#### 5. COVID Application Backlogs and MDUFA Hold Updates

QA Block 5-1
CLARIFIED QUESTION: Could you give an update on the MDUFA hold or backlog?
CLARIFIED ANSWER: Due to the COVID-related workload, FDA shifted resources from non-COVID MDUFA work, leading to a backlog. These holds are not indefinite and specifics will be communicated to sponsors.
VERBATIM QUESTION: Could you give an update on the MDUFA hold or backlog?
VERBATIM ANSWER: Yes so just for those that don't know because of the volume of COVID applications all applications in total for COVID, you know, including pre-EUA, original UAs, EUA supplement amendments we're seeing somewhere between 200 and 300 new applications a month still. And that's just a tremendous volume but obviously it has great importance for the country. And as a result we did move headcount from non-COVID work to COVID work and in the process took people off of regular MDUFA non-COVID NWX-FDA OC work. And as a result we, you know, because of the work load volume we did put files on hold. And those holds, I was going to say, are not indefinite. They will come to a very specific end, no matter what file. So and all files will be treated equally and they - this is not an indefinite hold and we will be communicating that with each sponsor. So if we can't get back to it on the first hold, the next communication will spell out exactly when we can get back to that file. And so it will not go on indefinitely. Hopefully that addressed your question.
SPEAKER QUESTION: Vana Smith
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: MDUFA hold, COVID workload impact, EUA applications
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: Will the FDA communicate specific timelines for when they will address MDUFA files currently on hold?
CLARIFIED ANSWER: The FDA confirmed that holds on MDUFA files are not indefinite and that they will communicate specific timelines with sponsors, including exact timelines in future communications if immediate resolutions are unavailable.
VERBATIM QUESTION: Will the FDA communicate specific timelines for when they will address MDUFA files currently on hold?
VERBATIM ANSWER: Those holds, I was going to say, are not indefinite. They will come to a very specific end, no matter what file. So and all files will be treated equally and they - this is not an indefinite hold and we will be communicating that with each sponsor. So if we can't get back to it on the first hold, the next communication will spell out exactly when we can get back to that file. And so it will not go on indefinitely.
SPEAKER QUESTION: Vana Smith
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: MDUFA file timelines, FDA communication, COVID workload impact
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: How many new COVID-19 related applications does the FDA receive monthly, and does this impact non-COVID related work?
CLARIFIED ANSWER: The FDA receives 200 to 300 new COVID-19-related applications monthly, which has led to reallocating staff from non-COVID work, impacting MDUFA submissions and other non-COVID activities.
VERBATIM QUESTION: How many new COVID-19 related applications does the FDA receive monthly, and does this impact non-COVID related work?
VERBATIM ANSWER: Yes so just for those that don't know because of the volume of COVID applications all applications in total for COVID, you know, including pre- EUA, original UAs, EUA supplement amendments we're seeing somewhere between 200 and 300 new applications a month still. And that's just a tremendous volume but obviously it has great importance for the country. And as a result we did move headcount from non-COVID work to COVID work and in the process took people off of regular MDUFA non-COVID NWX-FDA OC work.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19-related applications, Impact on non-COVID work, MDUFA backlog
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What steps is the FDA taking to ensure that all files, including MDUFA, are treated equally despite staffing reallocation?
CLARIFIED ANSWER: Due to the volume of COVID-related applications, FDA reallocated staff from non-COVID MDUFA work, resulting in some files being placed on hold. However, these holds are not indefinite, and all files will be treated equally with clear communication provided to sponsors about timelines.
VERBATIM QUESTION: What steps is the FDA taking to ensure that all files, including MDUFA, are treated equally despite staffing reallocation?
VERBATIM ANSWER: Yes so just for those that don't know because of the volume of COVID applications all applications in total for COVID, you know, including pre- EUA, original UAs, EUA supplement amendments we're seeing somewhere between 200 and 300 new applications a month still. And that's just a tremendous volume but obviously it has great importance for the country. And as a result we did move headcount from non-COVID work to COVID work and in the process took people off of regular MDUFA non-COVID NWX-FDA OC work. And as a result we, you know, because of the work load volume we did put files on hold. And those holds, I was going to say, are not indefinite. They will come to a very specific end, no matter what file. So and all files will be treated equally and they - this is not an indefinite hold and we will be communicating that with each sponsor. So if we can't get back to it on the first hold, the next communication will spell out exactly when we can get back to that file. And so it will not go on indefinitely.
SPEAKER QUESTION: Vana Smith
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: MDUFA file holds, Staffing reallocation, Communication with sponsors
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: Will sponsors directly receive updates about the status of their delayed files under MDUFA?
CLARIFIED ANSWER: FDA will communicate directly with each sponsor regarding the status of their delayed MDUFA files, including updates on specific timelines.
VERBATIM QUESTION: Will sponsors directly receive updates about the status of their delayed files under MDUFA?
VERBATIM ANSWER: So and all files will be treated equally and they - this is not an indefinite hold and we will be communicating that with each sponsor. So if we can't get back to it on the first hold, the next communication will spell out exactly when we can get back to that file.
SPEAKER QUESTION: Vana Smith
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: MDUFA file updates, sponsor communication, COVID impact on reviews
REVIEW FLAG: False


#### 6. Mobile App Validation for Antigen Test Equivalency Across Platforms

QA Block 6-1
CLARIFIED QUESTION: Has the agency authorized any mobile medical applications for COVID-19 or otherwise that are supported on both iOS and Android?
CLARIFIED ANSWER: FDA suggests validating mobile medical apps across various device models (both iOS and Android) due to differences in hardware and conditions (e.g., cameras, lighting). Analytical studies using positive samples can demonstrate equivalency without patient samples, and validated models should be clearly labeled.
VERBATIM QUESTION: Has the agency authorized any mobile medical applications for COVID-19 or otherwise that are supported on both iOS and Android?
VERBATIM ANSWER: Okay. So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Mobile medical apps, Device equivalency studies, Validation requirements
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Were there any specific requirements for test developers to show equivalence between iOS and Android platforms?
CLARIFIED ANSWER: FDA recommends studies to demonstrate equivalency between iOS and Android models, covering high, medium, and low positive samples under different conditions, but patient samples are not required. Validated models should be specified in the labeling.
VERBATIM QUESTION: Were there any specific requirements for test developers to show equivalence between iOS and Android platforms?
VERBATIM ANSWER: Okay. So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: equivalency studies, iOS and Android platforms, test validation
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Are there any specific areas of concern in supporting a system on both iOS and Android platforms?
CLARIFIED ANSWER: FDA emphasizes that cell phones differ across models and platforms, which impact performance due to factors like cameras, resolution, and lighting conditions. A study showing model equivalency is recommended, using analytical work with different conditions, rather than actual patient samples. Validated models should be listed in the labeling, as performance outside tested models is unknown.
VERBATIM QUESTION: Are there any specific areas of concern in supporting a system on both iOS and Android platforms?
VERBATIM ANSWER: Okay. So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Platform equivalency, iOS and Android diagnostics, Study validation
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What studies are required to support equivalency between iOS and Android platforms for mobile medical applications?
CLARIFIED ANSWER: FDA recommends conducting a study to show performance equivalency between iOS and Android devices, which can use analytical work with high, medium, and low positive samples under different conditions. Validation can focus on one or more device models, and devices tested should be listed on the product label.
VERBATIM QUESTION: What studies are required to support equivalency between iOS and Android platforms for mobile medical applications?
VERBATIM ANSWER: So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Mobile medical applications, Equivalency studies, Device validation
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Is a mobile medical app that captures images to assess test results and provides reporting functions valid for use on different models of iOS and Android devices?
CLARIFIED ANSWER: FDA recommends conducting validation studies to demonstrate equivalency between different models of iOS and Android devices for mobile medical apps that capture images for test result assessment and reporting. These studies should use analytical work under various conditions, and validated models should be explicitly stated in the labeling.
VERBATIM QUESTION: Is a mobile medical app that captures images to assess test results and provides reporting functions valid for use on different models of iOS and Android devices?
VERBATIM ANSWER: So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Mobile medical apps, iOS and Android device validation, Diagnostic test imaging
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: What guidance can the FDA provide for study design and validation of different iOS and Android device models for regulatory authorization?
CLARIFIED ANSWER: FDA advises validating different iOS and Android models by showing equivalency in performance through analytical studies using high, medium, and low positive samples under various lighting conditions. While patient samples are not required, manufacturers should outline their validation plans, document supported models in labeling, and acknowledge uncertain performance outside tested models.
VERBATIM QUESTION: What guidance can the FDA provide for study design and validation of different iOS and Android device models for regulatory authorization?
VERBATIM ANSWER: Okay. So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Study design for device equivalency, Validation of iOS and Android, Regulatory requirements
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: What factors should be considered when designing an equivalency study for mobile medical apps that analyze test results, especially regarding different cell phone models?
CLARIFIED ANSWER: Factors include variability in phone models, camera resolutions, lighting conditions, and handling. Validation can use analytical work with high, medium, and low positive samples in different conditions. Developers should propose a study design and ensure validated models are specified in labeling.
VERBATIM QUESTION: What factors should be considered when designing an equivalency study for mobile medical apps that analyze test results, especially regarding different cell phone models?
VERBATIM ANSWER: Okay. So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: equivalency studies, mobile medical apps, cell phone model validation
REVIEW FLAG: False

QA Block 6-9
CLARIFIED QUESTION: Can analytical studies using high, medium, and low positive samples in varying lighting conditions suffice for equivalency validation?
CLARIFIED ANSWER: Analytical studies using high, medium, and low positive samples in varying lighting conditions can suffice for showing equivalency between different models, and these do not require actual patient samples. The FDA suggests proposing a study design to validate device performance.
VERBATIM QUESTION: Can analytical studies using high, medium, and low positive samples in varying lighting conditions suffice for equivalency validation?
VERBATIM ANSWER: Okay. So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: equivalency validation, mobile device performance, analytical studies
REVIEW FLAG: False

QA Block 6-10
CLARIFIED QUESTION: Is it mandatory to perform studies on actual patient samples when validating equivalence for mobile medical apps?
CLARIFIED ANSWER: It is not mandatory to perform studies on actual patient samples. Validation can use analytical work with samples of varying positivity levels and different lighting conditions to demonstrate equivalency between models.
VERBATIM QUESTION: Is it mandatory to perform studies on actual patient samples when validating equivalence for mobile medical apps?
VERBATIM ANSWER: They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation of mobile medical apps, equivalency studies, patient sample alternatives
REVIEW FLAG: False

QA Block 6-11
CLARIFIED QUESTION: Should test developers propose their own study designs for validating equivalency across models?
CLARIFIED ANSWER: Test developers are encouraged to propose their own study designs to validate equivalency across models. Analytical testing under varying conditions and listing validated models in labeling are key steps.
VERBATIM QUESTION: Should test developers propose their own study designs for validating equivalency across models?
VERBATIM ANSWER: So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Study designs for validation, Model equivalency in testing
REVIEW FLAG: False

QA Block 6-12
CLARIFIED QUESTION: Are test developers required to specify the validated cell phone models in product labeling?
CLARIFIED ANSWER: FDA requires validated cell phone models to be stated in the product labeling as performance outside those models would be unknown.
VERBATIM QUESTION: Are test developers required to specify the validated cell phone models in product labeling?
VERBATIM ANSWER: But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validated cell phone models, product labeling
REVIEW FLAG: False

QA Block 6-13
CLARIFIED QUESTION: What should be included in a validation study to demonstrate performance equivalence between different cell phone models?
CLARIFIED ANSWER: The FDA advises including analytical validation using models accepted in a study to show performance equivalence across cell phone models. Validation should involve high, medium, and low positive samples under varying lighting conditions to demonstrate equivalence. Additionally, the test labeling should specify the validated phone models.
VERBATIM QUESTION: What should be included in a validation study to demonstrate performance equivalence between different cell phone models?
VERBATIM ANSWER: Okay. So that obviously cell phones are different even within a family, you know, iOS or Android, the different models are available and have different cameras, different resolutions. Lighting may play a big role exactly how you hold something. And that could have differences between even within a family of cell phones models. So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't. So there's a great deal of flexibility here. And so the best thing to do is to propose a study design however you want to run your study and then how you would propose to validate the different models that you would allow in the authorization. But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation study design, Cell phone model equivalency, COVID-19 mobile app performance
REVIEW FLAG: False

QA Block 6-14
CLARIFIED QUESTION: What are the FDA's expectations for handling performance not known outside of the validated phone models?
CLARIFIED ANSWER: The FDA expects the labeling to state the validated phone models, noting that performance outside those models is unknown.
VERBATIM QUESTION: What are the FDA's expectations for handling performance not known outside of the validated phone models?
VERBATIM ANSWER: But we do think that in the labeling the models that you've validated should be stated and that, you know, obviously performance outside of that would not be known.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validated phone models, performance expectations, labeling requirements
REVIEW FLAG: False


#### 7. Guidance on Validation Using Archived Flu Samples

QA Block 7-1
CLARIFIED QUESTION: Does FDA have any guidance on how recent FDA cleared comparative assays should be used for flu A and B in a multi-analyte molecular test validation?
CLARIFIED ANSWER: FDA does not have limitations on the authorization date of comparator tests for non-SARS targets. Any FDA-authorized molecular test is acceptable.
VERBATIM QUESTION: Does FDA have any guidance on how recent FDA cleared comparative assays should be used for flu A and B in a multi-analyte molecular test validation?
VERBATIM ANSWER: I'm not aware of any limitations on the authorized comparator test for non- SARS targets. As long as it's FDA authorized molecular test that would be acceptable to us.
SPEAKER QUESTION: Roxanne Chan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: flu A and B comparator assays, validation of molecular tests
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Does FDA have any guidance on the age and storage conditions of archived flu samples to be applicable in clinical validation?
CLARIFIED ANSWER: FDA allows the use of banked samples for non-SARS targets but requires stability studies to support the use of older samples.
VERBATIM QUESTION: Does FDA have any guidance on the age and storage conditions of archived flu samples to be applicable in clinical validation?
VERBATIM ANSWER: Let's talk about banked samples, you can use banked samples. We do ask that you support through stability studies the use of say the oldest of those samples but there's no problem using banked samples for the non-SARS target.
SPEAKER QUESTION: Roxanne Chan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: banked samples, clinical validation, flu samples
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What stability studies are required to validate the use of the oldest banked samples in clinical validation?
CLARIFIED ANSWER: FDA requires stability studies to validate the use of the oldest banked samples, but there is no issue using them for non-SARS targets.
VERBATIM QUESTION: What stability studies are required to validate the use of the oldest banked samples in clinical validation?
VERBATIM ANSWER: Let's talk about banked samples, you can use banked samples. We do ask that you support through stability studies the use of say the oldest of those samples but there's no problem using banked samples for the non-SARS target.
SPEAKER QUESTION: Roxanne Chan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: stability studies, banked samples, non-SARS targets
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Is there a post-market requirement for prospective studies when using banked samples to validate non-SARS analytes?
CLARIFIED ANSWER: FDA requires a post-market commitment to conduct prospective studies for non-SARS analytes validated using banked samples, acknowledging that low flu circulation makes banked samples necessary.
VERBATIM QUESTION: Is there a post-market requirement for prospective studies when using banked samples to validate non-SARS analytes?
VERBATIM ANSWER: There will be a post-market commitment to do a prospective study for those analytes but we understand that especially flu, there's very little flu circulating so bank sample is really the only way that you're going to be able to assess that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Post-market prospective studies, Validation with banked samples, Non-SARS analytes
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Are there any limitations on using FDA authorized comparator tests specifically for non-SARS targets?
CLARIFIED ANSWER: FDA is not aware of any limitations on the use of authorized comparator tests for non-SARS targets, provided the test is an FDA-authorized molecular test.
VERBATIM QUESTION: Are there any limitations on using FDA authorized comparator tests specifically for non-SARS targets?
VERBATIM ANSWER: I'm not aware of any limitations on the authorized comparator test for non- SARS targets. As long as it's FDA authorized molecular test that would be acceptable to us.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparator tests, non-SARS targets, FDA authorizations
REVIEW FLAG: False


#### 8. EUA Software Modifications: Submission Requirements and FDA Guidance

QA Block 8-1
CLARIFIED QUESTION: What is the agency's view on software changes that improve performance in the context of the pandemic?
CLARIFIED ANSWER: The FDA encourages developers planning software changes affecting performance to seek pre-approval during the EUA process, detailing modifications, performance evaluations, and criteria. If outlined in the authorization, re-submission might not be required unless labeling or data updates are involved. For point-of-care or home tests, reauthorization is required prior to launch. Kits for high complexity labs can validate and launch with data submission while under FDA review.
VERBATIM QUESTION: What is the agency's view on software changes that improve performance in the context of the pandemic?
VERBATIM ANSWER: So it depends. So we are encouraging developers if they know they're going to make software modifications that may alter the performance and hopefully improve performance or you just don't know if it's going to alter the performance but you're planning on doing it, that during the EUA process NWX-FDA OC that you secure from the FDA sort of pre-approval of pre-authorization of a change or modification which would include covering the kinds of changes you would make and how you would assess performance and what would represent an adequate performance acceptable after you evaluate the change. And if that is built into your authorization then if everything looks great and it meets everything that the FDA and the developer expected to see there would be no need to come in for a modified change unless there would be an updated labeling, anything, any different instructions or if you wanted to actually show that you have better performance and modify the data in your EUA authorization to show that your test is now more sensitive. If you had not - if you already have in EUA authorization and you have not preset that change modification procedure then we yes, we'd want to see the data as an amendment. Now if you - if this is a point of care or a home test we would need to see that data and review it and reauthorize prior to launching that. However if you have a kit for use in high complexity labs you can validate that, submit the validation to us and immediately launch that change while we review it and prior to making
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Software changes in diagnostics, EUA process, Performance improvement
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: If after authorization a developer improves the algorithm, increasing PPA from 90% to 92% without usability changes, would this improvement require a new EUA or an EUA amendment?
CLARIFIED ANSWER: It depends. If the change was pre-approved within the EUA process, a new modification would often not be needed unless there were updates to labeling or performance claims. Otherwise, data would need to be submitted as an amendment. For point-of-care or home tests, reauthorization is needed before launching; high-complexity lab kits may submit validation and launch before reauthorization.
VERBATIM QUESTION: If after authorization a developer improves the algorithm, increasing PPA from 90% to 92% without usability changes, would this improvement require a new EUA or an EUA amendment?
VERBATIM ANSWER: So it depends. So we are encouraging developers if they know they're going to make software modifications that may alter the performance and hopefully improve performance or you just don't know if it's going to alter the performance but you're planning on doing it, that during the EUA process NWX-FDA OC that you secure from the FDA sort of pre-approval of pre-authorization of a change or modification which would include covering the kinds of changes you would make and how you would assess performance and what would represent an adequate performance acceptable after you evaluate the change. And if that is built into your authorization then if everything looks great and it meets everything that the FDA and the developer expected to see there would be no need to come in for a modified change unless there would be an updated labeling, anything, any different instructions or if you wanted to actually show that you have better performance and modify the data in your EUA authorization to show that your test is now more sensitive. If you had not - if you already have in EUA authorization and you have not preset that change modification procedure then we yes, we'd want to see the data as an amendment. Now if you - if this is a point of care or a home test we would need to see that data and review it and reauthorize prior to launching that. However if you have a kit for use in high complexity labs you can validate that, submit the validation to us and immediately launch that change while we review it and prior to making
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA amendment process, Algorithm performance improvement, Pre-approval for modifications
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: What process should developers follow to obtain pre-authorization from the FDA for planned software modifications during the EUA process?
CLARIFIED ANSWER: FDA encourages developers planning software modifications during the EUA process to secure pre-authorization by detailing the types of changes, performance assessments, and acceptable results. If pre-authorization is granted and expectations are met, further submission is generally unnecessary unless labeling or other updates are needed.
VERBATIM QUESTION: What process should developers follow to obtain pre-authorization from the FDA for planned software modifications during the EUA process?
VERBATIM ANSWER: So it depends. So we are encouraging developers if they know they're going to make software modifications that may alter the performance and hopefully improve performance or you just don't know if it's going to alter the performance but you're planning on doing it, that during the EUA process NWX-FDA OC that you secure from the FDA sort of pre-approval of pre-authorization of a change or modification which would include covering the kinds of changes you would make and how you would assess performance and what would represent an adequate performance acceptable after you evaluate the change. And if that is built into your authorization then if everything looks great and it meets everything that the FDA and the developer expected to see there would be no need to come in for a modified change unless there would be an updated labeling, anything, any different instructions or if you wanted to actually show that you have better performance and modify the data in your EUA authorization to show that your test is now more sensitive.
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Software modifications during EUA, Pre-authorization process, Performance impact
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: What specific criteria does the FDA use to determine whether software changes require only validation or an EUA amendment?
CLARIFIED ANSWER: The FDA suggests developers pre-authorize software modifications during the EUA process to streamline approval. Changes pre-approved as part of the EUA may not require an amendment unless labeling or data updates are necessary. If pre-authorization wasn't secured, data must be submitted as an amendment, and for certain test types, prior reauthorization is required. High-complexity lab tests may launch with validation submitted during FDA review.
VERBATIM QUESTION: What specific criteria does the FDA use to determine whether software changes require only validation or an EUA amendment?
VERBATIM ANSWER: So it depends. So we are encouraging developers if they know they're going to make software modifications that may alter the performance and hopefully improve performance or you just don't know if it's going to alter the performance but you're planning on doing it, that during the EUA process NWX-FDA OC that you secure from the FDA sort of pre-approval of pre-authorization of a change or modification which would include covering the kinds of changes you would make and how you would assess performance and what would represent an adequate performance acceptable after you evaluate the change. And if that is built into your authorization then if everything looks great and it meets everything that the FDA and the developer expected to see there would be no need to come in for a modified change unless there would be an updated labeling, anything, any different instructions or if you wanted to actually show that you have better performance and modify the data in your EUA authorization to show that your test is now more sensitive. If you had not - if you already have in EUA authorization and you have not preset that change modification procedure then we yes, we'd want to see the data as an amendment. Now if you - if this is a point of care or a home test we would need to see that data and review it and reauthorize prior to launching that. However if you have a kit for use in high complexity labs you can validate that, submit the validation to us and immediately launch that change while we review it and prior to making
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Criteria for EUA amendments, Software modifications, Validation vs amendment requirements
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Are certain types of COVID-19 diagnostic tests, like point-of-care or home tests, subject to additional review requirements before changes can be launched?
CLARIFIED ANSWER: Point-of-care or home COVID-19 tests require FDA review and reauthorization before changes can be launched. Tests for high-complexity labs can be launched immediately after submitting validation data to FDA.
VERBATIM QUESTION: Are certain types of COVID-19 diagnostic tests, like point-of-care or home tests, subject to additional review requirements before changes can be launched?
VERBATIM ANSWER: Now if you - if this is a point of care or a home test we would need to see that data and review it and reauthorize prior to launching that. However if you have a kit for use in high complexity labs you can validate that, submit the validation to us and immediately launch that change while we review it and prior to making
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test review, Point-of-care and home tests, EUA modification requirements
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Can developers immediately launch changes for high-complexity lab use kits after submitting validation data to the FDA?
CLARIFIED ANSWER: Developers can immediately launch changes for high-complexity lab use kits after submitting validation data to the FDA, while the FDA reviews it.
VERBATIM QUESTION: Can developers immediately launch changes for high-complexity lab use kits after submitting validation data to the FDA?
VERBATIM ANSWER: However if you have a kit for use in high complexity labs you can validate that, submit the validation to us and immediately launch that change while we review it and prior to making the EUA authorization decision.
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: high-complexity lab kits, validation submission, EUA process
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: What documentation is required to update labeling or instructions when modifying an EUA authorization?
CLARIFIED ANSWER: If an EUA includes pre-authorization for changes, updates to labeling or instructions may not require further submission unless significant changes occur. Otherwise, an amendment with supporting data is required.
VERBATIM QUESTION: What documentation is required to update labeling or instructions when modifying an EUA authorization?
VERBATIM ANSWER: And if that is built into your authorization then if everything looks great and it meets everything that the FDA and the developer expected to see there would be no need to come in for a modified change unless there would be an updated labeling, anything, any different instructions or if you wanted to actually show that you have better performance and modify the data in your EUA authorization to show that your test is now more sensitive. If you had not - if you already have in EUA authorization and you have not preset that change modification procedure then we yes, we'd want to see the data as an amendment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA modification, documentation requirements, labeling updates
REVIEW FLAG: False

QA Block 8-8
CLARIFIED QUESTION: Does the inclusion of improved sensitivity data in an EUA authorization update require a full review by the FDA?
CLARIFIED ANSWER: If the improved sensitivity data is for a point of care or home test, FDA must review and reauthorize before launch. For high-complexity lab kits, developers can validate and launch while FDA reviews the data.
VERBATIM QUESTION: Does the inclusion of improved sensitivity data in an EUA authorization update require a full review by the FDA?
VERBATIM ANSWER: If you had not - if you already have in EUA authorization and you have not preset that change modification procedure then we yes, we'd want to see the data as an amendment. Now if you - if this is a point of care or a home test we would need to see that data and review it and reauthorize prior to launching that. However if you have a kit for use in high complexity labs you can validate that, submit the validation to us and immediately launch that change while we review it and prior to making
SPEAKER QUESTION: Ron Domingo
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA modification, Improved sensitivity, FDA review requirements
REVIEW FLAG: False


#### 9. Guidelines for Recruiting Subjects in Molecular Testing Studies

QA Block 9-1
CLARIFIED QUESTION: What does FDA think about recruiting subjects who have had a positive antigen or PCR test in the past 48 hours for molecular test studies?
CLARIFIED ANSWER: FDA advises sponsors to present their study designs prior to starting when recruiting subjects who recently tested positive. Asymptomatic individuals can be included by linking testing programs and resampling positives, but the process must ensure blinding of prior results and include an appropriate ratio of negative samples as controls.
VERBATIM QUESTION: What does FDA think about recruiting subjects who have had a positive antigen or PCR test in the past 48 hours for molecular test studies?
VERBATIM ANSWER: Yes so this is something probably we want to take a look at prior to you starting this study if you don't want to have the study be at risk. But definitely I have publicly stated for accumulating multiple times I think on this town hall call and other settings as well that for enriching for asymptomatic individuals you can connect with some sort of regular testing program. And if they're positive then you can resample and use it in your test. We just want to know that design, when you do that we also of course want to see that you keep everybody blinded to the prior results and include at least equal number of negative results in that blinded retesting. So if somebody gets the test, they're negative then we would want a portion of them included as well as the portion, you know, that you need to get to the recommended number of positives for the study.
SPEAKER QUESTION: Karen Gerard
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: molecular test study enrollment, study design review, asymptomatic and blinded testing
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: What is the FDA's stance on using regular testing programs for recruiting asymptomatic subjects for molecular test studies?
CLARIFIED ANSWER: The FDA allows the use of regular testing programs for recruiting asymptomatic subjects, provided the design is reviewed beforehand. Blinded testing must include equal numbers of negative and positive results, with adequate positive cases sampled for the study.
VERBATIM QUESTION: What is the FDA's stance on using regular testing programs for recruiting asymptomatic subjects for molecular test studies?
VERBATIM ANSWER: Yes so this is something probably we want to take a look at prior to you starting this study if you don't want to have the study be at risk. But definitely I have publicly stated for accumulating multiple times I think on this town hall call and other settings as well that for enriching for asymptomatic individuals you can connect with some sort of regular testing program. And if they're positive then you can resample and use it in your test. We just want to know that design, when you do that we also of course want to see that you keep everybody blinded to the prior results and include at least equal number of negative results in that blinded retesting. So if somebody gets the test, they're negative then we would want a portion of them included as well as the portion, you know, that you need to get to the recommended number of positives for the study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Regular testing for recruitment, Asymptomatic molecular test studies, Blinded test designs
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: How should test developers design protocols to incorporate resampling from regular testing programs?
CLARIFIED ANSWER: Test developers can connect with regular testing programs for resampling asymptomatic individuals who test positive, while ensuring appropriate blinding and inclusion of an equal number of negative test results in the study.
VERBATIM QUESTION: How should test developers design protocols to incorporate resampling from regular testing programs?
VERBATIM ANSWER: Yes so this is something probably we want to take a look at prior to you starting this study if you don't want to have the study be at risk. But definitely I have publicly stated for accumulating multiple times I think on this town hall call and other settings as well that for enriching for asymptomatic individuals you can connect with some sort of regular testing program. And if they're positive then you can resample and use it in your test. We just want to know that design, when you do that we also of course want to see that you keep everybody blinded to the prior results and include at least equal number of negative results in that blinded retesting. So if somebody gets the test, they're negative then we would want a portion of them included as well as the portion, you know, that you need to get to the recommended number of positives for the study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test protocol design, resampling, blinded testing
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What are the FDA's expectations for blinding prior test results in prospective study designs?
CLARIFIED ANSWER: The FDA expects blinding of prior test results in prospective study designs and requires an equal portion of negative results to be included in the blinded retesting along with positive results to meet study recommendations.
VERBATIM QUESTION: What are the FDA's expectations for blinding prior test results in prospective study designs?
VERBATIM ANSWER: We just want to know that design, when you do that we also of course want to see that you keep everybody blinded to the prior results and include at least equal number of negative results in that blinded retesting. So if somebody gets the test, they're negative then we would want a portion of them included as well as the portion, you know, that you need to get to the recommended number of positives for the study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: blinding of prior results, prospective study design, negative and positive result requirements
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: How should developers select and incorporate a portion of negative samples to meet recommended study requirements?
CLARIFIED ANSWER: FDA advises incorporating negative samples in blinded retesting by including an equal portion of negatives as positives to meet study requirements while maintaining blinding and prior testing program designs.
VERBATIM QUESTION: How should developers select and incorporate a portion of negative samples to meet recommended study requirements?
VERBATIM ANSWER: But definitely I have publicly stated for accumulating multiple times I think on this town hall call and other settings as well that for enriching for asymptomatic individuals you can connect with some sort of regular testing program. And if they're positive then you can resample and use it in your test. We just want to know that design, when you do that we also of course want to see that you keep everybody blinded to the prior results and include at least equal number of negative results in that blinded retesting. So if somebody gets the test, they're negative then we would want a portion of them included as well as the portion, you know, that you need to get to the recommended number of positives for the study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: negative sample inclusion, study requirements, blinded testing
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Does the FDA recommend specific numbers or proportions of positive and negative samples to include in blinded retesting for molecular diagnostic studies?
CLARIFIED ANSWER: The FDA recommends keeping testing blinded and including equal numbers of negative and positive samples in blinded retesting to meet study requirements.
VERBATIM QUESTION: Does the FDA recommend specific numbers or proportions of positive and negative samples to include in blinded retesting for molecular diagnostic studies?
VERBATIM ANSWER: We just want to know that design, when you do that we also of course want to see that you keep everybody blinded to the prior results and include at least equal number of negative results in that blinded retesting. So if somebody gets the test, they're negative then we would want a portion of them included as well as the portion, you know, that you need to get to the recommended number of positives for the study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: blinded retesting, study design, molecular diagnostic tests
REVIEW FLAG: False


#### 10. Serology Test Differentiation Between Vaccination and Infection

QA Block 10-1
CLARIFIED QUESTION: Can you elaborate if serology tests that differentiate between vaccination and infection are of interest to the FDA?
CLARIFIED ANSWER: The FDA will prioritize reviewing serology test applications that differentiate between vaccination and infection if they are complete and supported by evidence. Study designs must be robust, and developers are advised to consult the FDA with their SOP to support claims.
VERBATIM QUESTION: Can you elaborate if serology tests that differentiate between vaccination and infection are of interest to the FDA?
VERBATIM ANSWER: Yes. If the application is complete and has evidence that could support such a claim, then we will make that review a high priority. The study designs for supporting such use so are not insignificant and so just look at that. And you probably want to run an SOP, a study design SOP by the FDA to see if that is going to support whatever claim that you may seek.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, differentiation of vaccination vs infection, FDA regulatory priorities
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: What are the expected components of a complete application for a serology test that differentiates between vaccination and infection?
CLARIFIED ANSWER: The FDA reviews complete applications that provide evidence supporting claims of differentiation between vaccination and infection as a high priority. Applicants should consider FDA review of their study design SOP for suitability in supporting their claims.
VERBATIM QUESTION: What are the expected components of a complete application for a serology test that differentiates between vaccination and infection?
VERBATIM ANSWER: Yes. If the application is complete and has evidence that could support such a claim, then we will make that review a high priority. The study designs for supporting such use so are not insignificant and so just look at that. And you probably want to run an SOP, a study design SOP by the FDA to see if that is going to support whatever claim that you may seek.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test application, differentiating vaccination vs infection, FDA review process
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What level of evidence is required to support claims for serology tests that differentiate between vaccination and infection?
CLARIFIED ANSWER: The FDA prioritizes reviews for serology tests that differentiate between vaccination and infection if the application is complete and supported by significant evidence. Submit a study design SOP to confirm it supports the intended claims.
VERBATIM QUESTION: What level of evidence is required to support claims for serology tests that differentiate between vaccination and infection?
VERBATIM ANSWER: Yes. If the application is complete and has evidence that could support such a claim, then we will make that review a high priority. The study designs for supporting such use so are not insignificant and so just look at that. And you probably want to run an SOP, a study design SOP by the FDA to see if that is going to support whatever claim that you may seek.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, differentiating vaccination vs. infection, evidence submission
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What specific study design considerations should test developers include to support such claims?
CLARIFIED ANSWER: FDA recommends conducting a thorough study design and consulting with FDA on a study design SOP to ensure it supports the intended claim.
VERBATIM QUESTION: What specific study design considerations should test developers include to support such claims?
VERBATIM ANSWER: The study designs for supporting such use so are not insignificant and so just look at that. And you probably want to run an SOP, a study design SOP by the FDA to see if that is going to support whatever claim that you may seek.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study design, serology test claims, FDA review process
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: How does the FDA evaluate study design SOPs for supporting claims related to serology tests?
CLARIFIED ANSWER: The FDA prioritizes reviews for complete applications with evidence supporting serology test claims. It advises running study design SOPs by the FDA to ensure support for intended claims.
VERBATIM QUESTION: How does the FDA evaluate study design SOPs for supporting claims related to serology tests?
VERBATIM ANSWER: Yes. If the application is complete and has evidence that could support such a claim, then we will make that review a high priority. The study designs for supporting such use so are not insignificant and so just look at that. And you probably want to run an SOP, a study design SOP by the FDA to see if that is going to support whatever claim that you may seek.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test claims, Study design SOPs, FDA evaluation
REVIEW FLAG: False


#### 11. FDA Requirements for Fresh and Banked Sample Testing

QA Block 11-1
CLARIFIED QUESTION: How is the FDA assessing the success of the five positive samples that aren't in transport media?
CLARIFIED ANSWER: The FDA assesses the five positive samples not in transport media by reviewing all data presented and using good scientific practices. They ensure sensitivity is not significantly reduced, while frozen samples could potentially improve assay sensitivity.
VERBATIM QUESTION: How is the FDA assessing the success of the five positive samples that aren't in transport media?
VERBATIM ANSWER: Yes, we'll look at all the data and make an assessment. Obviously if they're all negative that would be a problem, right? So the other thing just to fill out the responses, you know, getting negatives is really easy so we'd like to see all the negatives fresh. But you can enrich 25 of those 30 with bank samples. We know that in some cases freezing samples releases more target and actually may improve the sensitivity of the assay. So we would definitely like to see that there is no significant drop in sensitivity. But we look at all the data and we make the assessment based on the data that's presented and the best - and using the best good science to evaluate it.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Assessment of prospective samples, Sample sensitivity evaluation
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Are the five prospective positive samples included in the post-authorization collection?
CLARIFIED ANSWER: Yes, if five fresh positives and 25 banked samples are included premarket, the FDA would ask for 25 additional fresh samples postmarket to meet requirements.
VERBATIM QUESTION: Are the five prospective positive samples included in the post-authorization collection?
VERBATIM ANSWER: Yes so if you did five fresh and 25 banked post market, you know, everything else being equal an average submission we would, you know, no NWX-FDA OC outstanding concerns, we would ask for just 25 more fresh samples post market.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: prospective positive samples, post-authorization requirements, sample collection
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What happens if we have 25 banked samples and five prospective samples?
CLARIFIED ANSWER: FDA requires a minimum of 30 fresh samples. If premarket data includes only 25 banked and 5 fresh samples, the missing fresh samples must be collected in a post-market study.
VERBATIM QUESTION: What happens if we have 25 banked samples and five prospective samples?
VERBATIM ANSWER: Yes, so you - so we want to see complete data ultimately on 30 - a minimum of 30 fresh samples. So whatever you don't contribute to that 30 in the premarket, pre-authorization base we would like to see in the post - in the post market study.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample requirements, post-market studies, fresh vs banked samples
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: Can the 30 fresh results be a mixture of positive and negative samples?
CLARIFIED ANSWER: No, the FDA requires a minimum of 30 fresh positive samples per application for a point of care test. If fewer fresh positives are submitted pre-market, additional fresh positives must be provided post-market.
VERBATIM QUESTION: Can the 30 fresh results be a mixture of positive and negative samples?
VERBATIM ANSWER: No, no. No we want to see per application for a point of care test we want to see a minimum of 30 overall fresh positives. So you can - if you only do five fresh positives pre-market we would want to see five fresh positives, 25 fresh positives post market.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample requirements, point of care test, positive samples
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: What is the FDA's rationale for requiring negative samples to be fresh?
CLARIFIED ANSWER: The FDA requires negative samples to be fresh because obtaining negatives is straightforward, and freezing can sometimes increase target levels, potentially influencing assay sensitivity. Fresh negatives help ensure no significant sensitivity drop.
VERBATIM QUESTION: What is the FDA's rationale for requiring negative samples to be fresh?
VERBATIM ANSWER: So the other thing just to fill out the responses, you know, getting negatives is really easy so we'd like to see all the negatives fresh. But you can enrich 25 of those 30 with bank samples. We know that in some cases freezing samples releases more target and actually may improve the sensitivity of the assay. So we would definitely like to see that there is no significant drop in sensitivity. But we look at all the data and we make the assessment based on the data that's presented and the best - and using the best good science to evaluate it.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Negative sample requirements, Fresh vs. banked samples, Sensitivity concerns
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: Does the FDA consider frozen banked samples to potentially enhance assay sensitivity due to target release upon freezing?
CLARIFIED ANSWER: FDA acknowledges that freezing samples can release more target material, potentially improving assay sensitivity, and emphasizes ensuring that sensitivity does not significantly drop.
VERBATIM QUESTION: Does the FDA consider frozen banked samples to potentially enhance assay sensitivity due to target release upon freezing?
VERBATIM ANSWER: We know that in some cases freezing samples releases more target and actually may improve the sensitivity of the assay. So we would definitely like to see that there is no significant drop in sensitivity.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Frozen banked samples, Assay sensitivity, Target material release
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: Does the FDA require that testing performance for prospective samples not in transport media align with those in transport media?
CLARIFIED ANSWER: The FDA evaluates data to ensure there is no significant drop in sensitivity for prospective samples compared to those in transport media and bases assessments on good scientific practices.
VERBATIM QUESTION: Does the FDA require that testing performance for prospective samples not in transport media align with those in transport media?
VERBATIM ANSWER: We know that in some cases freezing samples releases more target and actually may improve the sensitivity of the assay. So we would definitely like to see that there is no significant drop in sensitivity. But we look at all the data and we make the assessment based on the data that's presented and the best - and using the best good science to evaluate it.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sample performance comparison, Sensitivity assessment, Scientific evaluation
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: Are there any specific requirements for the proportion of fresh samples in a mix of banked and fresh samples before and after market authorization?
CLARIFIED ANSWER: The FDA requires a total of 30 fresh positive samples per application for point-of-care tests, with the option to use enriched banked samples pre-market to expedite market entry. Any missing fresh positives pre-market must be completed post-market.
VERBATIM QUESTION: Are there any specific requirements for the proportion of fresh samples in a mix of banked and fresh samples before and after market authorization?
VERBATIM ANSWER: So we want to see a total of 30 fresh results but we are allowing pre- market the enrichment with banked in order to aid in getting particularly point of care tests onto the market as soon as possible in...Yes, go ahead....can be a mixture of positive and negatives correct?...No, no. No we want to see per application for a point of care test we want to see a minimum of 30 overall fresh positives. So you can - if you only do five fresh positives pre-market we would want to see five fresh positives, 25 fresh positives post market.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: fresh vs banked sample proportions, pre-market and post-market requirements
REVIEW FLAG: False

QA Block 11-10
CLARIFIED QUESTION: Does the FDA make any distinctions between swabs frozen directly versus those frozen in viral transport media for premarket decisions?
CLARIFIED ANSWER: The FDA does not distinguish between direct frozen swabs and those frozen in viral transport media but requires a complete data set for either type for premarket decisions.
VERBATIM QUESTION: Does the FDA make any distinctions between swabs frozen directly versus those frozen in viral transport media for premarket decisions?
VERBATIM ANSWER: What we want to see is for the bank that could be frozen direct swabs or it can be frozen in VTM. We want to see a complete set of data for that sample type, that frozen sample type in order to make our premarket decision. And we want to make sure with the fresh positives that the test performance is still holding up.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Premarket decisions, Sample freezing methods, Swab data requirements
REVIEW FLAG: False

QA Block 11-11
CLARIFIED QUESTION: What is the FDA's definition of a complete data set for banked samples in terms of premarket approval?
CLARIFIED ANSWER: FDA requires a complete data set for banked samples, including frozen direct swabs or those in VTM, to make premarket approval decisions. They also verify that test performance holds up with fresh positives.
VERBATIM QUESTION: What is the FDA's definition of a complete data set for banked samples in terms of premarket approval?
VERBATIM ANSWER: What we want to see is for the bank that could be frozen direct swabs or it can be frozen in VTM. We want to see a complete set of data for that sample type, that frozen sample type in order to make our premarket decision. And we want to make sure with the fresh positives that the test performance is still holding up.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: complete data set, premarket approval, banked samples
REVIEW FLAG: False


#### 12. Adding COVID-19 Markers to Existing Devices

QA Block 12-1
CLARIFIED QUESTION: If a manufacturer has a legally marketed device and they want to add a COVID-19 diagnostic to that device, is the information required for the EUA request limited to the validation of the assay itself without needing to provide technical information on the device if it's unchanged?
CLARIFIED ANSWER: The FDA confirms that if the device is unchanged, the necessary information is typically limited to assay validation. However, more specific guidance requires details about the platform.
VERBATIM QUESTION: If a manufacturer has a legally marketed device and they want to add a COVID-19 diagnostic to that device, is the information required for the EUA request limited to the validation of the assay itself without needing to provide technical information on the device if it's unchanged?
VERBATIM ANSWER: Yes and what I'm saying is without unique details to your platform I can't give you any more specific information today.
SPEAKER QUESTION: Shuru Romkular
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission requirements, assay validation, device information
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: If you're submitting an EUA for a COVID-19 assay on a marketed device, can you apply this assay to additional instruments of the same instrument family under the replacement reagent policy like a 510k cleared assay?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA for review by their ancillary COVID team for this scenario.
VERBATIM QUESTION: If you're submitting an EUA for a COVID-19 assay on a marketed device, can you apply this assay to additional instruments of the same instrument family under the replacement reagent policy like a 510k cleared assay?
VERBATIM ANSWER: I really recommend that you just write up your idea and send it in as a pre-EUA. And that will be and likely go to one of our ancillary COVID teams that would review this type of application.
SPEAKER QUESTION: Shuru Romkular
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, Replacement reagent policy, COVID-19 assay
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: Can the information provided for adding a cytokine assay to an already 510k cleared device be limited to the validation of the assay and not the instrument?
CLARIFIED ANSWER: Yes, the FDA indicated that the information can be limited to the validation of the assay, but more specific guidance requires details about the platform.
VERBATIM QUESTION: Can the information provided for adding a cytokine assay to an already 510k cleared device be limited to the validation of the assay and not the instrument?
VERBATIM ANSWER: Yes and what I'm saying is without unique details to your platform I can't give you any more specific information today.
SPEAKER QUESTION: Shuru Romkular
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Cytokine assay addition, 510k cleared device validation
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What other types of COVID-19 related assays beyond IL-6 have been authorized by the FDA?
CLARIFIED ANSWER: The FDA has authorized IL-6 assays, as well as serology, antigen, and molecular tests, including respiratory virus panels.
VERBATIM QUESTION: What other types of COVID-19 related assays beyond IL-6 have been authorized by the FDA?
VERBATIM ANSWER: Oh, so okay well, you know, we've authorized some IL-6 assays. I'm not sure other than IL-6 what we've done hasn't been either serology antigen or molecular including panels of respiratory viruses.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA assay authorizations, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: How does the FDA distinguish between adding inflammatory markers and direct SARS-CoV-2 diagnostic tests under EUA requirements?
CLARIFIED ANSWER: The FDA differentiates by considering if the added marker impacts other elements of the assay. Inflammatory markers such as cytokines for COVID-19 are reviewed differently than SARS-CoV-2 diagnostic tests. For EUA, manufacturers should submit a pre-EUA detailing the intended addition, as certain unique panels may require specific review by an ancillary team.
VERBATIM QUESTION: How does the FDA distinguish between adding inflammatory markers and direct SARS-CoV-2 diagnostic tests under EUA requirements?
VERBATIM ANSWER: So can you tell me a little bit more details about your assay? Is this a molecular panel you're adding SARS-CoV-2 to other respiratory or what is this, you know, what are the non-COVID targets on this assay and what is it doing? Oh, so okay well, you know, we've authorized some IL-6 assays. I'm not sure other than IL-6 what we've done hasn't been either serology antigen or molecular including panels of respiratory viruses. I think this is specific enough that you ought to come with, you know, a pre- EUA with what you plan on doing to add that because it doesn't sound like you're adding a SARS test to a, you know, a SARS either serology or a NWX-FDA OC diagnostic to for identification of the virus or exposure of the virus to another serology or direct test. So it sounds like you have inflammatory markers for some other purpose and you want to add a COVID-19 related inflammatory marker or something to your - or, you know, apply for the use of your device for a COVID-19. And so that is a - going to be a little bit more unique and will depend on your given panel. In general when you're adding something to the panel depending on how that panel works if the wells are all independent and there's no, you know, there's no change in those independent wells and you're just adding a new well for SARS or wells for SARS and it has no direct impact on the other wells, then that is going to really make it a more streamlined to validate the addition of those new marker - that new marker or markers because what you're adding doesn't impact the results of the other markers of the analytical result in the other markers. On the other hand if there's some sort of, you know, everything together and you're adding SARS probes into already a mix that adding that into the mix could alter the performance of the other marker. So I really recommend that you just write up your idea and send it in as a pre-EUA. And that will be and likely go to one of our ancillary COVID teams that would review this type of application. It doesn't go in with the regular mix of serology antigen or molecular.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, Inflammatory markers, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: Does combining new SARS probes with existing assay components require reevaluation of the performance of all components?
CLARIFIED ANSWER: If new SARS probes are added to independent assay wells without altering others, reevaluation is streamlined. However, if the probes are integrated into an existing mix, their addition could alter other components' performance.
VERBATIM QUESTION: Does combining new SARS probes with existing assay components require reevaluation of the performance of all components?
VERBATIM ANSWER: In general when you're adding something to the panel depending on how that panel works if the wells are all independent and there's no, you know, there's no change in those independent wells and you're just adding a new well for SARS or wells for SARS and it has no direct impact on the other wells, then that is going to really make it a more streamlined to validate the addition of those new marker - that new marker or markers because what you're adding doesn't impact the results of the other markers of the analytical result in the other markers. On the other hand if there's some sort of, you know, everything together and you're adding SARS probes into already a mix that adding that into the mix could alter the performance of the other marker.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: SARS probes integration, Assay component performance, Validation requirements
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: What steps are involved in the pre-EUA process for unique panels with inflammatory markers related to COVID-19?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA detailing the unique panel features. The process may vary depending on whether the new marker impacts existing markers' performance. If the panel's wells operate independently, validation is simpler. Otherwise, mixing probes may require additional evaluation. Unique cases go to ancillary COVID teams for review, not standard serology or molecular processes.
VERBATIM QUESTION: What steps are involved in the pre-EUA process for unique panels with inflammatory markers related to COVID-19?
VERBATIM ANSWER: Oh, so okay well, you know, we've authorized some IL-6 assays. I'm not sure other than IL-6 what we've done hasn't been either serology antigen or molecular including panels of respiratory viruses. I think this is specific enough that you ought to come with, you know, a pre-EUA with what you plan on doing to add that because it doesn't sound like you're adding a SARS test to a, you know, a SARS either serology or a NWX-FDA OC diagnostic to for identification of the virus or exposure of the virus to another serology or direct test. So it sounds like you have inflammatory markers for some other purpose and you want to add a COVID-19 related inflammatory marker or something to your - or, you know, apply for the use of your device for a COVID-19. And so that is a - going to be a little bit more unique and will depend on your given panel. In general when you're adding something to the panel depending on how that panel works if the wells are all independent and there's no, you know, there's no change in those independent wells and you're just adding a new well for SARS or wells for SARS and it has no direct impact on the other wells, then that is going to really make it a more streamlined to validate the addition of those new marker - that new marker or markers because what you're adding doesn't impact the results of the other markers of the analytical result in the other markers. On the other hand if there's some sort of, you know, everything together and you're adding SARS probes into already a mix that adding that into the mix could alter the performance of the other marker. So I really recommend that you just write up your idea and send it in as a pre-EUA. And that will be and likely go to one of our ancillary COVID teams that would review this type of application. It doesn't go in with the regular mix of serology antigen or molecular.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA process, Inflammatory markers, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: Are modifications to panels considered 'streamlined' additions if new components do not affect other panel components?
CLARIFIED ANSWER: Yes, modifications to panels are considered streamlined if the new components (e.g., wells for SARS) are independent and do not impact the performance or results of other markers.
VERBATIM QUESTION: Are modifications to panels considered 'streamlined' additions if new components do not affect other panel components?
VERBATIM ANSWER: In general when you're adding something to the panel depending on how that panel works if the wells are all independent and there's no, you know, there's no change in those independent wells and you're just adding a new well for SARS or wells for SARS and it has no direct impact on the other wells, then that is going to really make it a more streamlined to validate the addition of those new marker - that new marker or markers because what you're adding doesn't impact the results of the other markers of the analytical result in the other markers. On the other hand if there's some sort of, you know, everything together and you're adding SARS probes into already a mix that adding that into the mix could alter the performance of the other marker.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Panel modifications, Streamlined validation, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 12-9
CLARIFIED QUESTION: What team within the FDA handles applications with inflammatory markers that are not part of the typical COVID-19 test categories (e.g., serology, antigen, molecular)?
CLARIFIED ANSWER: The FDA recommends submitting a pre-EUA for applications involving inflammatory markers, which would likely be reviewed by an ancillary COVID team rather than the regular teams for serology, antigen, or molecular tests.
VERBATIM QUESTION: What team within the FDA handles applications with inflammatory markers that are not part of the typical COVID-19 test categories (e.g., serology, antigen, molecular)?
VERBATIM ANSWER: I really recommend that you just write up your idea and send it in as a pre-EUA. And that will be and likely go to one of our ancillary COVID teams that would review this type of application. It doesn't go in with the regular mix of serology antigen or molecular.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA process, Inflammatory marker applications, Ancillary COVID team
REVIEW FLAG: False


#### 13. Comparative Performance of iOS and Android Devices in Testing

QA Block 13-1
CLARIFIED QUESTION: Does the FDA prioritize equivalency of data between platforms like iOS and Android rather than how the equivalency is achieved?
CLARIFIED ANSWER: The FDA prioritizes equivalency in the performance data between platforms like iOS and Android, considering potential differences in algorithms, cameras, and other factors. The labeling must ensure accurate results.
VERBATIM QUESTION: Does the FDA prioritize equivalency of data between platforms like iOS and Android rather than how the equivalency is achieved?
VERBATIM ANSWER: Yes I mean I don't know how you would carry out the clinical study portion of this for the users whether you would allow any of their devices to be used or whether you're going to use one specific device in those studies. And, you know, it might be better to have multiple. Whatever the patients have as a device you use that and you look at the overall performance. Separate from that we would, because you may only get one result from an Android this model X and whatever and only one result from an iOS model seven. So we want to know more data about the comparative performance if NWX-FDA OC it's actually doing the reading of the test and making the reading results available to the patient. And obviously there as we discussed before there could be different - they could yield different performance measures based on the fact that the algorithms might be different, and cameras might be different, the resolutions might be different. The background lighting conditions maybe - they may be less or more sensitive to that. The other thing I thought about it is there's all sorts of modes of taken a picture with a smart phone, you know, the essentially portrait, and landscape and, you know, night and day and all those things can, you know, potentially impact the accurate reading of the result. We just want to make sure that whatever, you know, you're going to put in your labeling that they're all going to be accurate results.
SPEAKER QUESTION: Lynn Ko
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Data equivalency between platforms, iOS and Android diagnostics, Labeling accuracy
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What approaches does the FDA recommend for ensuring equivalency in clinical studies using different devices?
CLARIFIED ANSWER: The FDA emphasizes evaluating the overall performance of devices by collecting data on comparative performance across different platforms. Factors like varying algorithms, camera resolutions, and lighting conditions must be considered to ensure accuracy in labeling.
VERBATIM QUESTION: What approaches does the FDA recommend for ensuring equivalency in clinical studies using different devices?
VERBATIM ANSWER: Yes I mean I don't know how you would carry out the clinical study portion of this for the users whether you would allow any of their devices to be used or whether you're going to use one specific device in those studies. And, you know, it might be better to have multiple. Whatever the patients have as a device you use that and you look at the overall performance. Separate from that we would, because you may only get one result from an Android this model X and whatever and only one result from an iOS model seven. So we want to know more data about the comparative performance if NWX-FDA OC it's actually doing the reading of the test and making the reading results available to the patient. And obviously there as we discussed before there could be different - they could yield different performance measures based on the fact that the algorithms might be different, and cameras might be different, the resolutions might be different. The background lighting conditions maybe - they may be less or more sensitive to that. The other thing I thought about it is there's all sorts of modes of taken a picture with a smart phone, you know, the essentially portrait, and landscape and, you know, night and day and all those things can, you know, potentially impact the accurate reading of the result. We just want to make sure that whatever, you know, you're going to put in your labeling that they're all going to be accurate results.
SPEAKER QUESTION: Lynn Ko
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Device equivalency, Clinical studies, Comparative performance
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: How should developers handle differences in camera resolutions and algorithms across devices when validating performance?
CLARIFIED ANSWER: FDA advises developers to validate performance across multiple devices, accounting for differences in algorithms, camera resolutions, and lighting conditions. These factors can impact test results, so labeling must ensure accurate results regardless of device.
VERBATIM QUESTION: How should developers handle differences in camera resolutions and algorithms across devices when validating performance?
VERBATIM ANSWER: Yes I mean I don't know how you would carry out the clinical study portion of this for the users whether you would allow any of their devices to be used or whether you're going to use one specific device in those studies. And, you know, it might be better to have multiple. Whatever the patients have as a device you use that and you look at the overall performance. Separate from that we would, because you may only get one result from an Android this model X and whatever and only one result from an iOS model seven. So we want to know more data about the comparative performance if NWX-FDA OC it's actually doing the reading of the test and making the reading results available to the patient. And obviously there as we discussed before there could be different - they could yield different performance measures based on the fact that the algorithms might be different, and cameras might be different, the resolutions might be different. The background lighting conditions maybe - they may be less or more sensitive to that. The other thing I thought about it is there's all sorts of modes of taken a picture with a smart phone, you know, the essentially portrait, and landscape and, you know, night and day and all those things can, you know, potentially impact the accurate reading of the result. We just want to make sure that whatever, you know, you're going to put in your labeling that they're all going to be accurate results.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Camera resolution variability, Algorithm differences, Device validation
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Does the FDA require additional data to address performance variations between different smartphone models?
CLARIFIED ANSWER: The FDA requires comparative performance data between various smartphone models due to potential variations in algorithms, cameras, lighting conditions, and other factors.
VERBATIM QUESTION: Does the FDA require additional data to address performance variations between different smartphone models?
VERBATIM ANSWER: Yes I mean I don't know how you would carry out the clinical study portion of this for the users whether you would allow any of their devices to be used or whether you're going to use one specific device in those studies. And, you know, it might be better to have multiple. Whatever the patients have as a device you use that and you look at the overall performance. Separate from that we would, because you may only get one result from an Android this model X and whatever and only one result from an iOS model seven. So we want to know more data about the comparative performance if NWX-FDA OC it's actually doing the reading of the test and making the reading results available to the patient. And obviously there as we discussed before there could be different - they could yield different performance measures based on the fact that the algorithms might be different, and cameras might be different, the resolutions might be different. The background lighting conditions maybe - they may be less or more sensitive to that. The other thing I thought about it is there's all sorts of modes of taken a picture with a smart phone, you know, the essentially portrait, and landscape and, you know, night and day and all those things can, you know, potentially impact the accurate reading of the result. We just want to make sure that whatever, you know, you're going to put in your labeling that they're all going to be accurate results.
SPEAKER QUESTION: Lynn Ko
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone performance, data requirements, test equivalency
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: What labeling considerations should be accounted for when test accuracy could be affected by lighting conditions or phone orientation?
CLARIFIED ANSWER: FDA emphasizes that labeling should account for variables like lighting conditions and smartphone orientation (e.g., portrait or landscape mode) as they may affect test result accuracy.
VERBATIM QUESTION: What labeling considerations should be accounted for when test accuracy could be affected by lighting conditions or phone orientation?
VERBATIM ANSWER: The background lighting conditions maybe - they may be less or more sensitive to that. The other thing I thought about it is there's all sorts of modes of taken a picture with a smart phone, you know, the essentially portrait, and landscape and, you know, night and day and all those things can, you know, potentially impact the accurate reading of the result. We just want to make sure that whatever, you know, you're going to put in your labeling that they're all going to be accurate results.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Labeling considerations, Test accuracy, Lighting and orientation
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: Should developers evaluate the impact of different photo-taking modes (e.g., portrait, night mode) on test result accuracy?
CLARIFIED ANSWER: Developers should evaluate the impact of various photo-taking modes, like portrait or night mode, on test result accuracy and ensure accurate results for all modes included in labeling.
VERBATIM QUESTION: Should developers evaluate the impact of different photo-taking modes (e.g., portrait, night mode) on test result accuracy?
VERBATIM ANSWER: The other thing I thought about it is there's all sorts of modes of taken a picture with a smart phone, you know, the essentially portrait, and landscape and, you know, night and day and all those things can, you know, potentially impact the accurate reading of the result. We just want to make sure that whatever, you know, you're going to put in your labeling that they're all going to be accurate results.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: photo-taking modes, test result accuracy, device performance
REVIEW FLAG: False


#### 14. Impact of Denied EUA on Tested Samples

QA Block 14-1
CLARIFIED QUESTION: Can a diagnostic test for COVID-19 be sold while the EUA request is still pending FDA review?
CLARIFIED ANSWER: The FDA did not explicitly address selling a test during an EUA review in this excerpt but mentioned working with submitters if an EUA is denied.
VERBATIM QUESTION: Can a diagnostic test for COVID-19 be sold while the EUA request is still pending FDA review?
VERBATIM ANSWER: No direct answer regarding selling a test while an EUA request is pending FDA review was explicitly stated in this section. The conversation focuses instead on the impact of patient samples tested if an EUA request is denied and how the FDA would handle such cases collaboratively with the submitter.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA denial handling, Patient sample validity
REVIEW FLAG: True

QA Block 14-2
CLARIFIED QUESTION: If the EUA request is rejected, what would be the impact on patient samples that have already been tested?
CLARIFIED ANSWER: If the EUA request is rejected, the FDA would work with the party to assess the specific circumstances and determine actions, such as notifying clients or issuing corrected or invalidated test results.
VERBATIM QUESTION: If the EUA request is rejected, what would be the impact on patient samples that have already been tested?
VERBATIM ANSWER: That is something that we would work with you as we concluded our review and went to a denial. We would work with you depending on the impact of the incorrect or sorry, of the reported results whether we expected you to do a communication to all your clients or were to send out corrected test results or, you know, invalidated test results or there anything like that, it would depend on the specific circumstances and we would work directly with you on that.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA rejection, patient test samples, FDA guidance
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: Are tested patient samples still valid if the EUA request for a COVID-19 diagnostic test is denied?
CLARIFIED ANSWER: The FDA would work with the company after a denial to address the impact of reported results, potentially including client communication or corrected/invalidated results. Actions depend on specific circumstances.
VERBATIM QUESTION: Are tested patient samples still valid if the EUA request for a COVID-19 diagnostic test is denied?
VERBATIM ANSWER: That is something that we would work with you as we concluded our review and went to a denial. We would work with you depending on the impact of the incorrect or sorry, of the reported results whether we expected you to do a communication to all your clients or were to send out corrected test results or, you know, invalidated test results or there anything like that, it would depend on the specific circumstances and we would work directly with you on that.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA denial, tested patient samples, validity assessment
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Will there be a rejection agreement outlining necessary actions if a COVID-19 test's EUA is rejected?
CLARIFIED ANSWER: FDA would work with companies after an EUA denial to determine necessary actions, though this wouldn't be part of the formal denial decision.
VERBATIM QUESTION: Will there be a rejection agreement outlining necessary actions if a COVID-19 test's EUA is rejected?
VERBATIM ANSWER: Right. It wouldn't necessarily be part of the denial but it would be something that we would work with you on after a denial decision was made.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA rejection process, Post-denial procedures
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: Does the necessary response to a rejected EUA depend on specific circumstances?
CLARIFIED ANSWER: The FDA's necessary response to a rejected EUA would depend on the specific circumstances, such as the impact of reported results. The FDA would work directly with the submitter to address actions like client communication or result corrections.
VERBATIM QUESTION: Does the necessary response to a rejected EUA depend on specific circumstances?
VERBATIM ANSWER: That is something that we would work with you as we concluded our review and went to a denial. We would work with you depending on the impact of the incorrect or sorry, of the reported results whether we expected you to do a communication to all your clients or were to send out corrected test results or, you know, invalidated test results or there anything like that, it would depend on the specific circumstances and we would work directly with you on that.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA rejection response, FDA coordination, Impact on test results
REVIEW FLAG: False


#### 15. Guidance on Mutant Genotype Detection and Sample Stability Testing

QA Block 15-1
CLARIFIED QUESTION: Is there a minimum number of samples required for mutant genotype detection or confirmation according to the new guidance document?
CLARIFIED ANSWER: The FDA guidance does not specify a minimum number of samples for mutant genotype detection or confirmation, but a proposal can be submitted for consideration.
VERBATIM QUESTION: Is there a minimum number of samples required for mutant genotype detection or confirmation according to the new guidance document?
VERBATIM ANSWER: I don't believe that it gets into that level of detail, but that is something that you could come in with a proposal regarding.
SPEAKER QUESTION: Esther Yen
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: mutant genotype detection, sample requirements
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: In sample stability testing, are you required to use only natural samples or can contrived samples be supplemented?
CLARIFIED ANSWER: FDA believes that inactivated virus can be used for sample stability testing, but recommends consulting relevant templates or sending inquiries for confirmation.
VERBATIM QUESTION: In sample stability testing, are you required to use only natural samples or can contrived samples be supplemented?
VERBATIM ANSWER: I would have to look at the template to see what is recommended there. Let me see if find that very quickly and if not I will ask you to send that in. Okay I believe that you can use inactivated virus for sample stability.
SPEAKER QUESTION: Esther Yen
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: sample stability testing, use of contrived samples, inactivated virus
REVIEW FLAG: False


#### 16. Defining High Throughput Criteria for Laboratory Testing

QA Block 16-1
CLARIFIED QUESTION: What is the cutoff or order of magnitude being referred to for laboratory tests considered high priority due to significantly high throughput?
CLARIFIED ANSWER: The FDA has not established a firm cutoff for high-throughput tests as it varies based on factors like in-house submissions and the pandemic's progression. Specific inquiries can be sent to their mailbox for evaluation.
VERBATIM QUESTION: What is the cutoff or order of magnitude being referred to for laboratory tests considered high priority due to significantly high throughput?
VERBATIM ANSWER: Thanks for that question. I believe Tim addressed this a little bit last week on the call as well. We don't have a firm number that we've put out because this does change a little bit depending on other details such as, you know, submissions in-house and as the pandemic progresses. NWX-FDA OC So if you do have a specific question for your test and want them to know whether it would be considered high throughput or significantly high throughput you can send that in through the mailbox and we can take a look.
SPEAKER QUESTION: Laura Ferguson
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: high-throughput tests, laboratory test prioritization, FDA mailbox for inquiries
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: What level of throughput is considered significantly high?
CLARIFIED ANSWER: The FDA does not have a fixed number for significantly high throughput as it varies based on submissions and pandemic progression. Specific inquiries can be sent to their mailbox for evaluation.
VERBATIM QUESTION: What level of throughput is considered significantly high?
VERBATIM ANSWER: We don't have a firm number that we've put out because this does change a little bit depending on other details such as, you know, submissions in-house and as the pandemic progresses. So if you do have a specific question for your test and want them to know whether it would be considered high throughput or significantly high throughput you can send that in through the mailbox and we can take a look.
SPEAKER QUESTION: Laura Ferguson
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: high throughput, laboratory test criteria
REVIEW FLAG: False

QA Block 16-4
CLARIFIED QUESTION: How does the frequency or volume of test submissions in-house influence the designation of high throughput?
CLARIFIED ANSWER: FDA has no fixed cutoff for high throughput designation as it depends on factors like in-house test submissions and the evolving pandemic. Specific inquiries can be submitted via the mailbox.
VERBATIM QUESTION: How does the frequency or volume of test submissions in-house influence the designation of high throughput?
VERBATIM ANSWER: We don't have a firm number that we've put out because this does change a little bit depending on other details such as, you know, submissions in-house and as the pandemic progresses. NWX-FDA OC So if you do have a specific question for your test and want them to know whether it would be considered high throughput or significantly high throughput you can send that in through the mailbox and we can take a look.
SPEAKER QUESTION: Laura Ferguson
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: test throughput criteria, influence of submission frequency, pandemic impact
REVIEW FLAG: False

QA Block 16-5
CLARIFIED QUESTION: What process is recommended to seek clarification from the FDA regarding whether a specific test is considered high throughput?
CLARIFIED ANSWER: If you have a specific question regarding whether a test is considered high throughput, you can send it to the FDA's designated mailbox for clarification.
VERBATIM QUESTION: What process is recommended to seek clarification from the FDA regarding whether a specific test is considered high throughput?
VERBATIM ANSWER: So if you do have a specific question for your test and want them to know whether it would be considered high throughput or significantly high throughput you can send that in through the mailbox and we can take a look.
SPEAKER QUESTION: Laura Ferguson
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: high throughput tests, seeking FDA clarification, submission guidance
REVIEW FLAG: False


#### 17. Conducting Antigen Point-of-Care Studies in the US

QA Block 17-1
CLARIFIED QUESTION: Can an antigen point-of-care study be conducted in Brazil with Brazilian healthcare professionals if a justification of equivalency between Brazilian and US healthcare providers is submitted?
CLARIFIED ANSWER: FDA recommends conducting antigen point-of-care studies in the US due to differences in healthcare practices and provider training between countries. Alternate proposals can be submitted for consideration but should be sent in advance to avoid potential disagreement.
VERBATIM QUESTION: Can an antigen point-of-care study be conducted in Brazil with Brazilian healthcare professionals if a justification of equivalency between Brazilian and US healthcare providers is submitted?
VERBATIM ANSWER: So we definitely recommend that these studies be conducted in the US because we do - we have seen differences between populations in, you know, in the US and other countries specifically with how, you know, practice of medicine and how healthcare providers are trained, et cetera. If you have a proposal specific to your situation that you'd like us to consider we always consider alternate proposals and you can send that in. But we highly recommend that you do that in advance of starting a new study in case we do not agree with the proposal.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Antigen point-of-care studies, Study location requirements, Justification for alternate study settings
REVIEW FLAG: False

QA Block 17-2
CLARIFIED QUESTION: Can the point-of-care instructions for an antigen test kit be translated into Portuguese via a certified translator and still be used in the study?
CLARIFIED ANSWER: The FDA recommends conducting these studies in the US due to differences in medical practices and healthcare provider training across countries. Alternate proposals, including translated instructions, can be submitted for consideration but should be approved by the FDA before starting the study.
VERBATIM QUESTION: Can the point-of-care instructions for an antigen test kit be translated into Portuguese via a certified translator and still be used in the study?
VERBATIM ANSWER: So we definitely recommend that these studies be conducted in the US because we do - we have seen differences between populations in, you know, in the US and other countries specifically with how, you know, practice of medicine and how healthcare providers are trained, et cetera. If you have a proposal specific to your situation that you'd like us to consider we always consider alternate proposals and you can send that in. But we highly recommend that you do that in advance of starting a new study in case we do not agree with the proposal.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Translation of instructions, Testing locations, Study approval requirements
REVIEW FLAG: False

QA Block 17-3
CLARIFIED QUESTION: Can a study synopsis be submitted instead of a full clinical evaluation protocol to get clarity sooner?
CLARIFIED ANSWER: The FDA allows submission of the study synopsis instead of the full clinical evaluation protocol, but it is likely that additional details will be requested during the review.
VERBATIM QUESTION: Can a study synopsis be submitted instead of a full clinical evaluation protocol to get clarity sooner?
VERBATIM ANSWER: You can submit the synopsis. It is it's quite likely that we would request additional details as we take a look so
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: submission of study synopsis, clinical evaluation protocol
REVIEW FLAG: False

QA Block 17-4
CLARIFIED QUESTION: What alternative proposals might the FDA consider if conducting a study outside the United States?
CLARIFIED ANSWER: The FDA is open to examining alternative study proposals for conducting studies outside the United States, but recommends submitting them for review before starting the study to ensure agreement.
VERBATIM QUESTION: What alternative proposals might the FDA consider if conducting a study outside the United States?
VERBATIM ANSWER: If you have a proposal specific to your situation that you'd like us to consider we always consider alternate proposals and you can send that in. But we highly recommend that you do that in advance of starting a new study in case we do not agree with the proposal.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: alternative proposals, international studies, study approval process
REVIEW FLAG: False

QA Block 17-5
CLARIFIED QUESTION: What specific aspects of healthcare provider training or practice in Brazil might differ from the U.S., potentially impacting study outcomes?
CLARIFIED ANSWER: FDA recommends conducting studies in the U.S. due to differences in healthcare provider training and practices between the U.S. and other countries.
VERBATIM QUESTION: What specific aspects of healthcare provider training or practice in Brazil might differ from the U.S., potentially impacting study outcomes?
VERBATIM ANSWER: So we definitely recommend that these studies be conducted in the US because we do - we have seen differences between populations in, you know, in the US and other countries specifically with how, you know, practice of medicine and how healthcare providers are trained, et cetera.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: healthcare provider training, study location impact, practice of medicine
REVIEW FLAG: False

QA Block 17-6
CLARIFIED QUESTION: Is there a formal process for submitting alternate proposals to the FDA for review before initiating a study?
CLARIFIED ANSWER: FDA allows submission of alternate proposals for consideration and recommends doing so before starting a study in case the proposal is not approved.
VERBATIM QUESTION: Is there a formal process for submitting alternate proposals to the FDA for review before initiating a study?
VERBATIM ANSWER: If you have a proposal specific to your situation that you'd like us to consider we always consider alternate proposals and you can send that in. But we highly recommend that you do that in advance of starting a new study in case we do not agree with the proposal.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Submitting alternate study proposals, FDA review process
REVIEW FLAG: False

QA Block 17-7
CLARIFIED QUESTION: What additional details might the FDA request if only a study synopsis is submitted instead of a full clinical protocol?
CLARIFIED ANSWER: You may submit a study synopsis, but the FDA is likely to request additional details upon review.
VERBATIM QUESTION: And can I submit a study synopsis rather than the full protocol in order to get clarity sooner or do you require a full clinical evaluation protocol?
VERBATIM ANSWER: You can submit the synopsis. It is it's quite likely that we would request additional details as we take a look so
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: study synopsis, clinical protocol
REVIEW FLAG: False


#### 18. Clarification on Sample Requirements for Submission and Clinical Data

QA Block 18-1
CLARIFIED QUESTION: Can samples be collected retrospectively or prospectively for antigen performance testing?
CLARIFIED ANSWER: FDA requires a complete data set of 30 specimens, and while retrospective samples are acceptable, additional fresh samples should be included in the post-authorization phase.
VERBATIM QUESTION: Can samples be collected retrospectively or prospectively for antigen performance testing?
VERBATIM ANSWER: Right so we would want to see a complete data set of 30 specimens. Without knowing exactly which test you're referring to I can't comment on the ISU but we would want to see, you know, complete data set of 30. And then if you have additional fresh that would be on top of the 30 and we would ask for the rest of the 30 fresh to be in the post authorization.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antigen performance testing, sample collection, specimen requirements
REVIEW FLAG: False

QA Block 18-2
CLARIFIED QUESTION: Does the submission need to include five prospective samples without transport media while continuing to collect the 30 positives?
CLARIFIED ANSWER: FDA requires a complete data set of 30 specimens. Additional fresh samples would be considered separately and included as part of post-authorization data.
VERBATIM QUESTION: Does the submission need to include five prospective samples without transport media while continuing to collect the 30 positives?
VERBATIM ANSWER: Right so we would want to see a complete data set of 30 specimens. Without knowing exactly which test you're referring to I can't comment on the ISU but we would want to see, you know, complete data set of 30. And then if you have additional fresh that would be on top of the 30 and we would ask for the rest of the 30 fresh to be in the post authorization.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: submission requirements, prospective samples, post-authorization samples
REVIEW FLAG: False

QA Block 18-3
CLARIFIED QUESTION: Why does a recent IFU indicate an intended use for fresh samples but show clinical performance data based only on banked, unfrozen samples?
CLARIFIED ANSWER: FDA requires a complete dataset of 30 specimens for review. Additional fresh samples may be included as part of post-authorization studies.
VERBATIM QUESTION: Why does a recent IFU indicate an intended use for fresh samples but show clinical performance data based only on banked, unfrozen samples?
VERBATIM ANSWER: Right so we would want to see a complete data set of 30 specimens. Without knowing exactly which test you're referring to I can't comment on the ISU but we would want to see, you know, complete data set of 30. And then if you have additional fresh that would be on top of the 30 and we would ask for the rest of the 30 fresh to be in the post authorization.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: IFU sample criteria, clinical performance data, post-authorization requirements
REVIEW FLAG: False


#### 19. Guidance on Validating Alternative Mouthwash Collection for EUA

QA Block 19-1
CLARIFIED QUESTION: What does validation for a mouthwash collection alternative look like when amending an EUA for a test currently using nasal swabs?
CLARIFIED ANSWER: FDA recommends reviewing alternate specimen type validation information in the template as a starting point. If it doesn't apply, you can resubmit the question through the EUA mailbox, flagging the absence of a lead reviewer, and request further input.
VERBATIM QUESTION: What does validation for a mouthwash collection alternative look like when amending an EUA for a test currently using nasal swabs?
VERBATIM ANSWER: I would start by recommending that you take a look at the alternate specimen type validation information in the template. That would be a good starting point. And then if that does not seem like it is applicable to the situation you can submit the question again through the mailbox and just flag that you don't have a lead reviewer and so you would like to get some input. And if you want to direct that or ask that they include me on that email you can do that and they will flag it for me.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA amendment, Validation for mouthwash collection, Specimen type guidance
REVIEW FLAG: False

QA Block 19-2
CLARIFIED QUESTION: What should be done if there is no assigned primary reviewer for an EUA?
CLARIFIED ANSWER: If you have no assigned primary reviewer for an EUA, resubmit your question through the EUA mailbox, flag that there is no lead reviewer, and request input. You can also request that FDA personnel be included in the email for further assistance.
VERBATIM QUESTION: What should be done if there is no assigned primary reviewer for an EUA?
VERBATIM ANSWER: ...you can submit the question again through the mailbox and just flag that you don't have a lead reviewer and so you would like to get some input. And if you want to direct that or ask that they include me on that email you can do that and they will flag it for me.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: No primary reviewer, EUA guidance, Validation input
REVIEW FLAG: False

QA Block 19-3
CLARIFIED QUESTION: What is your email address for contacting regarding EUA-related questions?
CLARIFIED ANSWER: You can send emails to the EUA mailbox, and they will forward it to the appropriate person.
VERBATIM QUESTION: What is your email address for contacting regarding EUA-related questions?
VERBATIM ANSWER: Or you can just send it to the EUA mailbox and they'll add it - they'll forward it to me.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA contact email, EUA process
REVIEW FLAG: False

QA Block 19-4
CLARIFIED QUESTION: What steps should test developers follow if information in the alternate specimen validation section of the EUA template does not fully apply to their situation?
CLARIFIED ANSWER: If the alternate specimen validation section of the EUA template does not fully apply, test developers should submit their question through the EUA mailbox, flag that they do not have a lead reviewer, and request input. They can ask for the message to be directed to FDA staff for review.
VERBATIM QUESTION: What steps should test developers follow if information in the alternate specimen validation section of the EUA template does not fully apply to their situation?
VERBATIM ANSWER: ...the situation you can submit the question again through the mailbox and just flag that you don't have a lead reviewer and so you would like to get some input. And if you want to direct that or ask that they include me on that email you can do that and they will flag it for me.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: alternate specimen validation, EUA template guidance
REVIEW FLAG: False

QA Block 19-5
CLARIFIED QUESTION: Can developers directly request that a question be flagged for a specific FDA reviewer if they don't have an assigned primary reviewer?
CLARIFIED ANSWER: Developers can resubmit their question through the EUA mailbox, indicate that they do not have a lead reviewer, and request input or flag it for a specific FDA reviewer.
VERBATIM QUESTION: Can developers directly request that a question be flagged for a specific FDA reviewer if they don't have an assigned primary reviewer?
VERBATIM ANSWER: ...you can submit the question again through the mailbox and just flag that you don't have a lead reviewer and so you would like to get some input. And if you want to direct that or ask that they include me on that email you can do that and they will flag it for me.
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA reviewer assignment, EUA question submission
REVIEW FLAG: False

QA Block 19-6
CLARIFIED QUESTION: Is the alternate specimen validation guidance for saliva applicable to mouthwash collection methods?
CLARIFIED ANSWER: The FDA suggests reviewing the alternate specimen validation guidance for saliva to determine if it is applicable to mouthwash collection methods.
VERBATIM QUESTION: Is the alternate specimen validation guidance for saliva applicable to mouthwash collection methods?
VERBATIM ANSWER: Right. That's why I suggested taking a look at that alternate specimen which your right, it's for saliva to see if that information is applicable and then if you have additional questions
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: alternate specimen validation, saliva vs. mouthwash methods
REVIEW FLAG: False

QA Block 19-7
CLARIFIED QUESTION: How should developers proceed if they have additional questions after consulting the EUA templates?
CLARIFIED ANSWER: If developers have additional questions after consulting the EUA templates, they should submit their questions through the EUA mailbox, flagging the absence of a lead reviewer, and request input. They can also ask for the query to be directed to the FDA representative.
VERBATIM QUESTION: How should developers proceed if they have additional questions after consulting the EUA templates?
VERBATIM ANSWER: ...you can submit the question again through the mailbox and just flag that you don't have a lead reviewer and so you would like to get some input. And if you want to direct that or ask that they include me on that email you can do that and they will flag it for me.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA mailbox submission, Lead reviewer, Additional assistance
REVIEW FLAG: False


#### 20. Acceptable Methods and Bias in Antigen Test Validation

QA Block 20-1
CLARIFIED QUESTION: Is it acceptable to the FDA to run an in silico analysis on the protein alignments of the nuclear protein from each variant and map it against our antibody actuals to determine the performance risk of an antigen test?
CLARIFIED ANSWER: FDA recommends submitting the proposed plan for assessment and feedback before proceeding with the analysis.
VERBATIM QUESTION: Is it acceptable to the FDA to run an in silico analysis on the protein alignments of the nuclear protein from each variant and map it against our antibody actuals to determine the performance risk of an antigen test?
VERBATIM ANSWER: Is that something that is probably - it would probably be best if you can send in your proposed plan and we can take a look at it and get you some feedback.
SPEAKER QUESTION: Nisha Lee
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: in silico analysis, antigen test performance, FDA feedback
REVIEW FLAG: False

QA Block 20-2
CLARIFIED QUESTION: What type of test is this for?
CLARIFIED ANSWER: The test is a point-of-care (POC) antigen test.
VERBATIM QUESTION: What type of test is this for?
VERBATIM ANSWER: Oh this is for a POC antigen test.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Nisha Lee
TOPICS: test type, POC antigen test
REVIEW FLAG: False

QA Block 20-3
CLARIFIED QUESTION: What additional information should be included when submitting a proposed plan for FDA feedback on antigen test development?
CLARIFIED ANSWER: The FDA recommends submitting the proposed development plan, which they will review and provide feedback on.
VERBATIM QUESTION: What additional information should be included when submitting a proposed plan for FDA feedback on antigen test development?
VERBATIM ANSWER: It would probably be best if you can send in your proposed plan and we can take a look at it and get you some feedback.
SPEAKER QUESTION: Nisha Lee
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antigen test development, FDA feedback, proposed plan submission
REVIEW FLAG: False

QA Block 20-4
CLARIFIED QUESTION: How can bias introduced by enriching a study with known positives due to reduced positivity rates be addressed?
CLARIFIED ANSWER: The FDA clarified that enriching a study with known positives, while potentially necessary due to reduced positivity rates, can introduce bias. Study designs must include a plan to address such bias.
VERBATIM QUESTION: How can bias introduced by enriching a study with known positives due to reduced positivity rates be addressed?
VERBATIM ANSWER: Great thank you Irene. I just wanted to jump back to a question that we had earlier in the call about enrichment due to reduced positivity rates. Tim did address this a little bit with talking about, you know, the potential downfalls of enrichment but we just wanted to clarify that enrichment - enriching your study with known positives can cause bias. So we would expect your study design to include a plan for addressing that bias. So just wanted to jump back to that topic and make that clarification in case that I wasn't clear in the previous remarks.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Study design, Bias in enrichment, Positivity rate challenges
REVIEW FLAG: False

QA Block 20-5
CLARIFIED QUESTION: What resources or guidelines are available to help with study design to avoid bias related to enrichment?
CLARIFIED ANSWER: FDA clarified that enriching a study with known positives can cause bias and expects study designs to include plans for addressing such bias.
VERBATIM QUESTION: What resources or guidelines are available to help with study design to avoid bias related to enrichment?
VERBATIM ANSWER: Great thank you Irene. I just wanted to jump back to a question that we had earlier in the call about enrichment due to reduced positivity rates. Tim did address this a little bit with talking about, you know, the potential downfalls of enrichment but we just wanted to clarify that enrichment - enriching your study with known positives can cause bias. So we would expect your study design to include a plan for addressing that bias. So just wanted to jump back to that topic and make that clarification in case that I wasn't clear in the previous remarks.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: study design, enrichment bias, FDA recommendations
REVIEW FLAG: False

### removed qa blocks
QA Block 4-1
CLARIFIED QUESTION: Can you recommend a source for obtaining specimens positive for mutations?
CLARIFIED ANSWER: The FDA suggests using immune plasma or serum from patients exposed to the relevant virus genotype. However, it acknowledges the difficulty in sourcing such samples and currently has no specific recommendations.
VERBATIM QUESTION: Can you recommend a source for obtaining specimens positive for mutations?
VERBATIM ANSWER: Yes it would be in the case of serology tests it would be immune plasm or serum from a patient known to have been exposed by the virus that could - genotype that could impact your assay. So that's obviously going to be a challenging sample for anybody to accumulate. So we're certainly in the process of looking into that. but I have no solution. I have no recommendation at this point unfortunately.
SPEAKER QUESTION: Dee Dee Datra
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: specimens for mutations, serology tests, test development
REVIEW FLAG: False

QA Block 4-10
CLARIFIED QUESTION: Are there any current programs by the FDA to support access to immune serum or plasma for assay validation?
CLARIFIED ANSWER: The FDA does not currently have any programs to announce for supporting access to immune serum or plasma; however, they are considering these issues.
VERBATIM QUESTION: Are there any current programs by the FDA to support access to immune serum or plasma for assay validation?
VERBATIM ANSWER: But hopefully that's helpful enough and we hope, you know, that that immune serum will be available to developers. And, you know, we're certainly thinking about all of those things. so but I don't have any program to announce right now other than what I've just talked about as far as looking at amino acid changes in the serology epitope molecule.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Immune serum/plasma access, FDA assay support
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: What does the FDA mean by "files on hold" for non-COVID MDUFA work?
CLARIFIED ANSWER: The FDA has placed non-COVID MDUFA files on hold due to staff reallocation for COVID-19 applications, but these holds will not be indefinite. Communication will occur to specify when work on these files resumes.
VERBATIM QUESTION: What does the FDA mean by "files on hold" for non-COVID MDUFA work?
VERBATIM ANSWER: Yes so just for those that don't know because of the volume of COVID applications all applications in total for COVID, you know, including pre- EUA, original UAs, EUA supplement amendments we're seeing somewhere between 200 and 300 new applications a month still. And that's just a tremendous volume but obviously it has great importance for the country. And as a result we did move headcount from non-COVID work to COVID work and in the process took people off of regular MDUFA non-COVID NWX-FDA OC work. And as a result we, you know, because of the work load volume we did put files on hold. And those holds, I was going to say, are not indefinite. They will come to a very specific end, no matter what file. So and all files will be treated equally and they - this is not an indefinite hold and we will be communicating that with each sponsor. So if we can't get back to it on the first hold, the next communication will spell out exactly when we can get back to that file. And so it will not go on indefinitely.
SPEAKER QUESTION: Vana Smith
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-COVID MDUFA work, Files on hold, COVID-19 workload
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: Does the equivalency study for mobile medical apps need to include actual patient samples?
CLARIFIED ANSWER: Equivalency studies for mobile medical apps do not need to include actual patient samples. Analytical work with various conditions is sufficient.
VERBATIM QUESTION: Does the equivalency study for mobile medical apps need to include actual patient samples?
VERBATIM ANSWER: So it's best if there is a study showing equivalency between those. They don't have to be on actual patient samples. So you could validate with say with one model or you could validate with any of the models that you would accept in the study of home users. But then show basically with analytical work that NWX-FDA OC there's, you know, with high, medium and low positive samples and different lighting conditions, that the different models, you know, perform equivalently and which ones don't.
SPEAKER QUESTION: Joanne Gonzalez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mobile medical app equivalency, study requirements, patient samples
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: What criteria does the FDA use to evaluate any potential drop in assay sensitivity when using frozen samples?
CLARIFIED ANSWER: FDA assesses potential drops in assay sensitivity for frozen samples by analyzing the data presented and applying rigorous scientific evaluation to ensure no significant drop in sensitivity occurs.
VERBATIM QUESTION: What criteria does the FDA use to evaluate any potential drop in assay sensitivity when using frozen samples?
VERBATIM ANSWER: We know that in some cases freezing samples releases more target and actually may improve the sensitivity of the assay. So we would definitely like to see that there is no significant drop in sensitivity. But we look at all the data and we make the assessment based on the data that's presented and the best - and using the best good science to evaluate it.
SPEAKER QUESTION: Annie Bell
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: assay sensitivity, frozen sample evaluation
REVIEW FLAG: False

QA Block 16-3
CLARIFIED QUESTION: What factors does the FDA consider when determining if a test qualifies as high throughput?
CLARIFIED ANSWER: The FDA does not provide a specific numeric threshold for high throughput tests, as it varies based on submissions and the state of the pandemic. For specific cases, inquiries can be sent to their mailbox for evaluation.
VERBATIM QUESTION: What factors does the FDA consider when determining if a test qualifies as high throughput?
VERBATIM ANSWER: We don't have a firm number that we've put out because this does change a little bit depending on other details such as, you know, submissions in-house and as the pandemic progresses. NWX-FDA OC So if you do have a specific question for your test and want them to know whether it would be considered high throughput or significantly high throughput you can send that in through the mailbox and we can take a look.
SPEAKER QUESTION: Laura Ferguson
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: high throughput tests, evaluation criteria
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 10:25:31 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 20
##### Explicit Questions Extraction

##### Implicit Questions Extraction

#### Section 2 of 20
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 2-1: What is the difference between usability studies and user comprehension studies in the validation process for COVID-19 diagnostic tests?
QI 2-2: Why does the FDA recommend using questionnaires consistent with the 2016 human factors guidance for usability studies of diagnostic devices?
QI 2-3: What are the specific considerations for usability studies of IVDs compared to other types of user interface evaluations?
QI 2-4: Why doesn't the current template for non-lab tests include user comprehension studies, and when might these be added?
QI 2-5: What does the FDA recommend for addressing the risks of lay user misinterpretation of serology test results?
QI 2-6: What are the FDA's priorities for reviewing COVID-19 diagnostic tests, especially in different test categories (e.g., over-the-counter, prescription, point of care)?

#### Section 3 of 20
##### Explicit Questions Extraction
QE 3-1: Is an anterior nasal swab with no stopper allowable for use with children under 14 in an over-the-counter (OTC) context?
QE 3-2: Does the FDA have data suggesting that nasal swabs with no stopper are unsafe for children under 14 even for anterior nasal swabs?
QE 3-3: Is it acceptable for anterior nasal swabs to not have a stopper?
QE 3-4: Is the FDA requesting stoppers for mid-turbinate swabs?

##### Implicit Questions Extraction
QI 3-1: What specific safety measures, other than stoppers, does the FDA recommend for nasal swabs to ensure safety when used by non-healthcare individuals at home?
QI 3-2: Are adapters or other modifications, apart from stoppers, acceptable for ensuring the safety of children during home-based anterior or mid-turbinate swab testing?

#### Section 4 of 20
##### Explicit Questions Extraction
QE 4-1: Can you recommend a source for obtaining specimens positive for mutations?
QE 4-2: Is there any guidance on how to evaluate the performance of a serology test?
QE 4-3: Can FDA recommend a source to obtain specimens positive for the most prevalent mutations right now?

##### Implicit Questions Extraction
QI 4-1: What does the FDA mean by the 5% rule when evaluating mutations?
QI 4-2: How should a serology test developer assess the impact of non-epitope amino acid changes on assay performance?
QI 4-3: What are the risks involved in testing against less prevalent mutations or variants?
QI 4-4: What is the process for obtaining immune serum or plasma to assess the impact of specific mutations?
QI 4-5: What labeling requirements might apply to tests if significant mutations are detected?
QI 4-6: Is there specific guidance on evaluating assay epitopes for prevalent mutations and their effects?
QI 4-7: Are there any current programs by the FDA to support access to immune serum or plasma for assay validation?

#### Section 5 of 20
##### Explicit Questions Extraction
QE 5-1: Could you give an update on the MDUFA hold or backlog?

##### Implicit Questions Extraction
QI 5-1: What does the FDA mean by "files on hold" for non-COVID MDUFA work?
QI 5-2: Will the FDA communicate specific timelines for when they will address MDUFA files currently on hold?
QI 5-3: How many new COVID-19 related applications does the FDA receive monthly, and does this impact non-COVID related work?
QI 5-4: What steps is the FDA taking to ensure that all files, including MDUFA, are treated equally despite staffing reallocation?
QI 5-5: Will sponsors directly receive updates about the status of their delayed files under MDUFA?

#### Section 6 of 20
##### Explicit Questions Extraction
QE 6-1: Has the agency authorized any mobile medical applications for COVID-19 or otherwise that are supported on both iOS and Android?
QE 6-2: Were there any specific requirements for test developers to show equivalence between iOS and Android platforms?
QE 6-3: Are there any specific areas of concern in supporting a system on both iOS and Android platforms?
QE 6-4: What studies are required to support equivalency between iOS and Android platforms for mobile medical applications?
QE 6-5: Is a mobile medical app that captures images to assess test results and provides reporting functions valid for use on different models of iOS and Android devices?
QE 6-6: Does the equivalency study for mobile medical apps need to include actual patient samples?
QE 6-7: What guidance can the FDA provide for study design and validation of different iOS and Android device models for regulatory authorization?

##### Implicit Questions Extraction
QI 6-1: What factors should be considered when designing an equivalency study for mobile medical apps that analyze test results, especially regarding different cell phone models?
QI 6-2: Can analytical studies using high, medium, and low positive samples in varying lighting conditions suffice for equivalency validation?
QI 6-3: Is it mandatory to perform studies on actual patient samples when validating equivalence for mobile medical apps?
QI 6-4: Should test developers propose their own study designs for validating equivalency across models?
QI 6-5: Are test developers required to specify the validated cell phone models in product labeling?
QI 6-6: What should be included in a validation study to demonstrate performance equivalence between different cell phone models?
QI 6-7: What are the FDA's expectations for handling performance not known outside of the validated phone models?

#### Section 7 of 20
##### Explicit Questions Extraction
QE 7-1: Does FDA have any guidance on how recent FDA cleared comparative assays should be used for flu A and B in a multi-analyte molecular test validation?
QE 7-2: Does FDA have any guidance on the age and storage conditions of archived flu samples to be applicable in clinical validation?

##### Implicit Questions Extraction
QI 7-1: What stability studies are required to validate the use of the oldest banked samples in clinical validation?
QI 7-2: Is there a post-market requirement for prospective studies when using banked samples to validate non-SARS analytes?
QI 7-3: Are there any limitations on using FDA authorized comparator tests specifically for non-SARS targets?

#### Section 8 of 20
##### Explicit Questions Extraction
QE 8-1: What is the agency's view on software changes that improve performance in the context of the pandemic?
QE 8-2: If after authorization a developer improves the algorithm, increasing PPA from 90% to 92% without usability changes, would this improvement require a new EUA or an EUA amendment?

##### Implicit Questions Extraction
QI 8-1: What process should developers follow to obtain pre-authorization from the FDA for planned software modifications during the EUA process?
QI 8-2: What specific criteria does the FDA use to determine whether software changes require only validation or an EUA amendment?
QI 8-3: Are certain types of COVID-19 diagnostic tests, like point-of-care or home tests, subject to additional review requirements before changes can be launched?
QI 8-4: Can developers immediately launch changes for high-complexity lab use kits after submitting validation data to the FDA?
QI 8-5: What documentation is required to update labeling or instructions when modifying an EUA authorization?
QI 8-6: Does the inclusion of improved sensitivity data in an EUA authorization update require a full review by the FDA?

#### Section 9 of 20
##### Explicit Questions Extraction
QE 9-1: What does FDA think about recruiting subjects who have had a positive antigen or PCR test in the past 48 hours for molecular test studies?

##### Implicit Questions Extraction
QI 9-1: What is the FDA's stance on using regular testing programs for recruiting asymptomatic subjects for molecular test studies?
QI 9-2: How should test developers design protocols to incorporate resampling from regular testing programs?
QI 9-3: What are the FDA's expectations for blinding prior test results in prospective study designs?
QI 9-4: How should developers select and incorporate a portion of negative samples to meet recommended study requirements?
QI 9-5: Does the FDA recommend specific numbers or proportions of positive and negative samples to include in blinded retesting for molecular diagnostic studies?

#### Section 10 of 20
##### Explicit Questions Extraction
QE 10-1: Can you elaborate if serology tests that differentiate between vaccination and infection are of interest to the FDA?

##### Implicit Questions Extraction
QI 10-1: What are the expected components of a complete application for a serology test that differentiates between vaccination and infection?
QI 10-2: What level of evidence is required to support claims for serology tests that differentiate between vaccination and infection?
QI 10-3: What specific study design considerations should test developers include to support such claims?
QI 10-4: How does the FDA evaluate study design SOPs for supporting claims related to serology tests?

#### Section 11 of 20
##### Explicit Questions Extraction
QE 11-1: How is the FDA assessing the success of the five positive samples that aren't in transport media?
QE 11-2: Are the five prospective positive samples included in the post-authorization collection?
QE 11-3: What happens if we have 25 banked samples and five prospective samples?
QE 11-4: Can the 30 fresh results be a mixture of positive and negative samples?

##### Implicit Questions Extraction
QI 11-1: What is the FDA's rationale for requiring negative samples to be fresh?
QI 11-2: Does the FDA consider frozen banked samples to potentially enhance assay sensitivity due to target release upon freezing?
QI 11-3: What criteria does the FDA use to evaluate any potential drop in assay sensitivity when using frozen samples?
QI 11-4: Does the FDA require that testing performance for prospective samples not in transport media align with those in transport media?
QI 11-5: Are there any specific requirements for the proportion of fresh samples in a mix of banked and fresh samples before and after market authorization?
QI 11-6: Does the FDA make any distinctions between swabs frozen directly versus those frozen in viral transport media for premarket decisions?
QI 11-7: What is the FDA's definition of a complete data set for banked samples in terms of premarket approval?

#### Section 12 of 20
##### Explicit Questions Extraction
QE 12-1: If a manufacturer has a legally marketed device and they want to add a COVID-19 diagnostic to that device, is the information required for the EUA request limited to the validation of the assay itself without needing to provide technical information on the device if it's unchanged?
QE 12-2: If you're submitting an EUA for a COVID-19 assay on a marketed device, can you apply this assay to additional instruments of the same instrument family under the replacement reagent policy like a 510k cleared assay?
QE 12-3: Can the information provided for adding a cytokine assay to an already 510k cleared device be limited to the validation of the assay and not the instrument?

##### Implicit Questions Extraction
QI 12-1: What other types of COVID-19 related assays beyond IL-6 have been authorized by the FDA?
QI 12-2: How does the FDA distinguish between adding inflammatory markers and direct SARS-CoV-2 diagnostic tests under EUA requirements?
QI 12-3: Does combining new SARS probes with existing assay components require reevaluation of the performance of all components?
QI 12-4: What steps are involved in the pre-EUA process for unique panels with inflammatory markers related to COVID-19?
QI 12-5: Are modifications to panels considered 'streamlined' additions if new components do not affect other panel components?
QI 12-6: What team within the FDA handles applications with inflammatory markers that are not part of the typical COVID-19 test categories (e.g., serology, antigen, molecular)?

#### Section 13 of 20
##### Explicit Questions Extraction
QE 13-1: Does the FDA prioritize equivalency of data between platforms like iOS and Android rather than how the equivalency is achieved?

##### Implicit Questions Extraction
QI 13-1: What approaches does the FDA recommend for ensuring equivalency in clinical studies using different devices?
QI 13-2: How should developers handle differences in camera resolutions and algorithms across devices when validating performance?
QI 13-3: Does the FDA require additional data to address performance variations between different smartphone models?
QI 13-4: What labeling considerations should be accounted for when test accuracy could be affected by lighting conditions or phone orientation?
QI 13-5: Should developers evaluate the impact of different photo-taking modes (e.g., portrait, night mode) on test result accuracy?

#### Section 14 of 20
##### Explicit Questions Extraction
QE 14-1: Can a diagnostic test for COVID-19 be sold while the EUA request is still pending FDA review?
QE 14-2: If the EUA request is rejected, what would be the impact on patient samples that have already been tested?
QE 14-3: Are tested patient samples still valid if the EUA request for a COVID-19 diagnostic test is denied?
QE 14-4: Will there be a rejection agreement outlining necessary actions if a COVID-19 test's EUA is rejected?
QE 14-5: Does the necessary response to a rejected EUA depend on specific circumstances?

##### Implicit Questions Extraction

#### Section 15 of 20
##### Explicit Questions Extraction
QE 15-1: Is there a minimum number of samples required for mutant genotype detection or confirmation according to the new guidance document?
QE 15-2: In sample stability testing, are you required to use only natural samples or can contrived samples be supplemented?

##### Implicit Questions Extraction

#### Section 16 of 20
##### Explicit Questions Extraction
QE 16-1: What is the cutoff or order of magnitude being referred to for laboratory tests considered high priority due to significantly high throughput?
QE 16-2: What level of throughput is considered significantly high?

##### Implicit Questions Extraction
QI 16-1: What factors does the FDA consider when determining if a test qualifies as high throughput?
QI 16-2: How does the frequency or volume of test submissions in-house influence the designation of high throughput?
QI 16-3: What process is recommended to seek clarification from the FDA regarding whether a specific test is considered high throughput?

#### Section 17 of 20
##### Explicit Questions Extraction
QE 17-1: Can an antigen point-of-care study be conducted in Brazil with Brazilian healthcare professionals if a justification of equivalency between Brazilian and US healthcare providers is submitted?
QE 17-2: Can the point-of-care instructions for an antigen test kit be translated into Portuguese via a certified translator and still be used in the study?
QE 17-3: Can a study synopsis be submitted instead of a full clinical evaluation protocol to get clarity sooner?

##### Implicit Questions Extraction
QI 17-1: What alternative proposals might the FDA consider if conducting a study outside the United States?
QI 17-2: What specific aspects of healthcare provider training or practice in Brazil might differ from the U.S., potentially impacting study outcomes?
QI 17-3: Is there a formal process for submitting alternate proposals to the FDA for review before initiating a study?
QI 17-4: What additional details might the FDA request if only a study synopsis is submitted instead of a full clinical protocol?

#### Section 18 of 20
##### Explicit Questions Extraction
QE 18-1: Can samples be collected retrospectively or prospectively for antigen performance testing?
QE 18-2: Does the submission need to include five prospective samples without transport media while continuing to collect the 30 positives?
QE 18-3: Why does a recent IFU indicate an intended use for fresh samples but show clinical performance data based only on banked, unfrozen samples?

##### Implicit Questions Extraction

#### Section 19 of 20
##### Explicit Questions Extraction
QE 19-1: What does validation for a mouthwash collection alternative look like when amending an EUA for a test currently using nasal swabs?
QE 19-2: What should be done if there is no assigned primary reviewer for an EUA?
QE 19-3: What is your email address for contacting regarding EUA-related questions?

##### Implicit Questions Extraction
QI 19-1: What steps should test developers follow if information in the alternate specimen validation section of the EUA template does not fully apply to their situation?
QI 19-2: Can developers directly request that a question be flagged for a specific FDA reviewer if they don't have an assigned primary reviewer?
QI 19-3: Is the alternate specimen validation guidance for saliva applicable to mouthwash collection methods?
QI 19-4: How should developers proceed if they have additional questions after consulting the EUA templates?

#### Section 20 of 20
##### Explicit Questions Extraction
QE 20-1: Is it acceptable to the FDA to run an in silico analysis on the protein alignments of the nuclear protein from each variant and map it against our antibody actuals to determine the performance risk of an antigen test?
QE 20-2: What type of test is this for?

##### Implicit Questions Extraction
QI 20-1: What additional information should be included when submitting a proposed plan for FDA feedback on antigen test development?
QI 20-2: How can bias introduced by enriching a study with known positives due to reduced positivity rates be addressed?
QI 20-3: What resources or guidelines are available to help with study design to avoid bias related to enrichment?
